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Abstract: 
TKI inhibitors have revolutionised CML therapy and the goals for management have 
shifted from finding newer therapies to optimising existing treatment approaches. We 
have tried to optimise CML therapy by identifying poor responders early by molecular 
monitoring, improve adherence by using self reported adherence and optimise 
intolerance by actively changing TKIs to overcome side effects. BCR-ABL PCR of 
<10% at 3 months and <1% at 6 months have become an accepted standard after the 
publication by Marin et al. We tried to combine the two measurements and showed that 
3 month milestone predicts poor responders and is sufficient to consider changing 
therapy and that an additional measurement at 6 months does not add any further 
value. Most existing methods of determining adherence to medications are financially 
impossible to replicate on a day to day basis or too labour intensive. We tried to 
measure adherence by 4 different questionnaire based methods (visual adherence 
scale, Lu’s scale, Haynes method and DAMS scale) and correlate it with clinical 
responses. We have showed that adherence by all methods correlated with clinical 
responses and Haynes method which quantifies adherence based on number of doses 
of medications missed over the last 7 days was the best indicator of adherence 
amongst all. We further looked at the interactions of daily routine, communication with 
the physician; access to internet and patients views on taking the medications with 
adherence to therapy and adherence was shown to be influenced by all of them. 
Majority of the patients on TKI therapy appeared to be anxious and nearly half of them 
depressed. Patients with a better QOL had improved adherences. We propose a model 
based on 4 questions with the most significance on multivariate analysis to be possibly 
used as a surrogate for adherence methods. It has been shown that intolerance affects 
adherence and hence outcomes. We have tried to improve intolerance by switching TKI 
therapy in patients who had attained CCyR and with chronic low grade side effects and 
showed that the side effects improved and all patients had further improvement in the 
molecular milestones with deepening responses.  
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Chapter I. Introduction 
 
Chronic myeloid leukaemia is a clonal myeloproliferative disorder characterised by a 
balanced translocation of chromosomes 9 and 22, resulting in a Philadelphia chromosome1.  
The  research that led to treatments for CML has over the years resulted in a much deeper 
understanding of the biology behind it and has formed the basis and blue print for targeted 
therapies in oncology. Today, with improved cure rates, CML is considered more of a 
chronic condition with the aims directed more towards optimising therapy to improve 
outcomes even further. 
I.1 Aetiology & Incidence 
The aetiology behind chronic myeloid leukaemia is unknown 2, 3. But there have been many 
postulations like effects of radiation, especially when increasing numbers of CML cases 
were seen in Japan after the Hiroshima bombing in 1945. The other evidence towards 
ionising radiation as a causative is from increased incidence in people with ankylosing 
spondylitis and others who have received radiotherapy and radiologists from their 
occupational exposure2.  
The incidence of CML worldwide has been quoted at 0.6 to 2 per 100,000 population4. The 
numbers seem to be slightly higher in the western world. Caucasians and afro-Caribbeans 
appear to be more prone to the disease as compared to other ethnic races5. The incidence 
increases with age and appears to be skewed towards men than women with a ratio 
between 1.3 & 1.8. The prevalence of the disease is increasing worldwide due to the 
tremendous success and increasing life span of CML patients. In the USA, 4870 new cases 
are estimated to be diagnosed annually and around 700 new cases in the UK6. Overall, CML 
accounts for 7 - 20 % of all leukaemias. 
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I.2 History of CML: 
Chronic myeloid leukaemia (CML) was the first leukaemia to be described7. Dr. Alfred 
Donne, a french physicist first possibly described a condition similar to CML way back in 
18422, 8. It was not until 3 years later that a physician from Scotland, Dr. David Craigie 
described a patient with fever, leucocytosis and Splenomegaly and later after 3 more such 
cases, with the help of his colleague and pathologist, Dr. John Bennett performed an 
autopsy and described their findings in 1845 in the Edinburgh Medical and Surgical Journal9.  
Simultaneously the German physician Virchow described a similar patient with autopsy 
findings in a journal soon after the British pair. Virchow coined the descriptive term “Weisses 
Blut” or “white blood”; this was based on the Greek (λνκοs and αı µα) and became in 
German “Leukamie.” Virchow is also credited with the view that the cause of the disease 
was a primary alteration in hematopoiesis10-12.  
There was a further 30 years following on from the discovery of CML, when Ernst Neumann 
recognised that the leukaemia originated in the bone marrow13, 14. There was a further 100 
years following this before any serious development with regards to understanding the 
disease really began. It started in Pennsylvania in the 1960’s with two cytogeneticists Peter 
Nowel and David Hungerford, who made a groundbreaking discovery that eventually led to 
the discovery of the molecular abnormalities associated with CML, potentially enabling its 
cure15. They discovered abnormally small G-group chromosome that we now call the 
Philadelphia chromosome (Ph). The name Philadelphia was given by some colleagues from 
Scotland in appreciation for their work. The chromosome was initially labelled as Ph1 in the 
hope that it was the beginning of many, but eventually on realisation that it was the only 
causative, became Ph. 
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Thirteen years later, with introduction of improved banding techniques the Ph chromosome 
was further characterised by Janet Rowley and colleagues, who were able to show in 1973 
that it was a truncated version of chromosome 22 (designated 22q-) and was the result of 
reciprocal translocation of genetic material between chromosomes 9 and 22 [designated 
t(9;22)]16. 
The early 1980s saw the identification of the two genes that flank the translocation 
breakpoint. The ABL gene (now renamed ABL1) from chromosome 9 had been known as 
the human homolog of a murine leukaemia virus; while the translocation partner from 
chromosome 22 was termed BCR for breakpoint cluster region, since DNA breaks occurred 
in a relatively small genomic region17, 18. It was later confirmed the relation between the 
BCR-ABL1 fusion gene and the Ph chromosome in CML patients.  
Of great importance was the discovery that the protein derived from the BCR-ABL1 gene 
had protein-tyrosine kinase (TK) activity that was deregulated compared with normal ABL1 
and correlated with its ability to transform cells to a malignant phenotype19. Several groups 
later reported that a CML-like disease could be induced in mice transplanted with bone 
marrow infected with a BCR-ABL1 retrovirus. This proved that BCR-ABL1 is the causative 
agent of the disease and not just a marker20, 21. 
I.3 Biology & pathogenesis of CML: 
A single, pluripotent, haematopoietic stem cell (HSC) acquires the Philadelphia (Ph) 
chromosome carrying the BCR-ABL1 fusion gene, provides its progeny with a proliferative 
advantage over normal haematopoietic elements and thus allows the Ph-positive clone 
gradually to displace residual normal haematopoiesis, resulting in CML is well established8.  
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The Ph chromosome is a shortened chromosome 22 (22q-) that results from a balanced, 
reciprocal translocation between the long arms of chromosome 9 and 22, designated 
t(9;22)(q34;q11) 16(figure 1).  
                                  
Figure 1- Schematic diagram of the translocation that creates the Ph chromosome 
 
  
The translocation results in the bulk of the ABL1 
(Abelson) proto-oncogene normally found in 
chromosome 9 translocated into a relatively small, 
5.8Kb genomic region on chromosome 22, that was 
named the breakpoint cluster region or BCR22. 
The classic BCR-ABL1 gene of CML results from the 
fusion of parts of two normal genes: the ABL gene on chromosome 9 (now renamed ABL1) 
and the BCR gene on chromosome 22 8. The breakpoints within the ABL1 occur either 
upstream of exon Ib, downstream of exon Ia, or more frequently, between exons Ib and Ia 23 
(Figure 2). 
In most patients with CML and in one-third of those with Ph-positive B-cell acute 
lymphoblastic leukaemia (Ph+ B-ALL) the breakpoints within BCR occur at a 5.8-kilobase 
(kb) area spanning exons e12-e16 (formerly called b1-b5), referred to as the major 
breakpoint cluster region (M-bcr). Alternative splicing gives rise to fusion transcripts with 
either b2a2 or b3a2 junctions that generate a 210-kDa protein (p210BCR-ABL1)24. 
  
Figure 2- Schematic representation of the ABL1 and BCR genes 
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The resulting BCR-ABL1 kinase contains a series of functionally distinct domains (figure 3). 
The tyrosine kinase encoded by the SRC-homology 1 (SH1) domain of the ABL1 component 
is undoubtedly the most crucial for oncogenic transformation. Other important motifs in the 
ABL1 portion are the protein interaction SRC-homology 2 (SH2) and the C-terminal actin-
binding and DNA binding domains24.   . 
                   Figure 3- Functional domains of p210BCR-ABL1 
 
 
On the BCR moiety, the coiled-coil motif encoded by the first BCR exon is responsible for 
the dimerization of the oncoprotein; a tyrosine at position 177 is crucial for the binding of 
adaptor proteins such as growth factor receptor bound protein 2; the N-terminal 
phosphoserine and phosphothreonine residues are required for interaction with SH2 
containing proteins, including ABL1 itself (figure 3). The leukaemogenic potential of 
p210BCR-ABL1 resides in the fact that the normally regulated tyrosine kinase activity of the 
ABL1 protein is constitutively activated by the juxtaposition of ‘alien’ BCR sequences. BCR 
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acts by promoting dimerization of the oncoprotein, such that the two adjacent BCR-ABL 
molecules phosphorylate each other on tyrosine residues. 
The uncontrolled kinase activity of BCR-ABL1 then supersedes the physiologic functions of 
the normal ABL1 enzyme by interacting with a variety of effector proteins. The key pathways 
implicated are those involving RAS, mitogen-activated protein (MAP) kinases, signal 
transducers and activators of transcription (STAT), phosphatidylinositol 3-kinase (PI3K) and 
MYC8.  
Most of the interactions are mediated by tyrosine phosphorylation and require the binding of 
BCR-ABL1 to adapter proteins such as growth factor receptor-bound protein 2 (GRB2), 
DOK, CRK, CRK-like proteins, SHC and casitas B lineage lymphoma protein 8. The net 
result is deregulated cellular proliferation, decreased adherence of leukaemia cells to the 
bone marrow stroma and a reduced apoptotic response to mutagenic stimuli. 
I.4 Clinical picture and manifestations: 
CML is characterized by a triphasic course that includes a chronic phase (CP), an 
intermediate or accelerated phase (AP) and an acute or blastic phase (BP)24. These days 
with the advent of TKI therapies and earlier diagnosis, the middle stage has become quite 
rare. At the time of diagnosis, more than 80% of patients are in CP, which is asymptomatic 
in approximately 40% of patients, being discovered during routine laboratory workup.  
From historical data, patients diagnosed with CP had a median survival of approximately 5 
years, and unless the disease was controlled or eliminated, they eventually transformed to a 
terminal or BP after a median of 3 to 5 years2.  
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The prognosis for patients with BP is poor, with a median survival of 3 – 6 months. Prior to 
introduction of TKI’s, approximately two thirds of the patients go through an intermediate 
phase known as AP before progressing to BP with a median survival of 1 – 2 years2.  
As a result of routine examination, the incidence of asymptomatic presentations in CP-CML 
has increased dramatically from 15% to 40% – 50%. There has been also a decrease in the 
presenting features of advanced phase disease2.  
Chronic Phase 
The commonest physical finding present in more than three-quarters of CML patients is an 
enlarged spleen and symptoms at the time of presentation are often attributed either to it or 
to anaemia25. These include fatigue and left upper abdominal pain or mass. Patients with 
CML are often diagnosed with leukocytosis, with white blood cell counts > 50 x 109/L. In rare 
situations, the leukocytosis can lead to retinal haemorrhage and signs of hyper viscosity 
such as priapism, cerebrovascular accidents, tinnitus, confusion, and stupor.  
Advanced phase (accelerated and blastic phases)  
In contrast to patients in chronic phase, patients in the advanced phase are more likely to 
experience symptoms, including weight loss, fever, night sweats and bone pains. Anaemia, 
infectious complications and bleeding are also common among these patients26. 
Subcutaneous nodules or haemorrhagic tender skin lesions, lymphadenopathy and central 
nervous system (CNS) leukaemia may also occur. Other features of progressive disease 
include increased blasts and basophils, resistance to therapy, increasing splenomegaly, 
cytogenetic clonal evolution, thrombocytosis or thrombocytopenia27. In the majority of 
patients, the progression in between phases is relatively insidious but distinct. 
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I.5 Prognostic factors: 
Sokal 
The Sokal prognostic score arose from a study of 813 patients with non-blastic Ph+ CML, 
which was designed to distinguish between patients with good and poor prognosis28. This 
study was conducted at a time when busulfan was the most common treatment modality. 
Clinical parameters (spleen size; blast-cell, platelet, and white cell count; and haemoglobin) 
were assessed as possible prognostic indicators. Importantly, all of the variables were 
assessed prior to the commencement of any therapy. Using a hazard ratio analysis, the 
most discriminatory factors were found to be spleen size, blast-cell percentage, patient age, 
and platelet count. The hazard ratio was then calculated for each patient, and patients were 
grouped into low-risk (Sokal score < 0.8), intermediate-risk (Sokal score 0.8–1.2), and high-
risk groups (Sokal score > 1.2). In the busulfan era, the Sokal score was found to be 
predictive of long-term survival and became a universal prognostic indicator for CML; it 
remains in use today.  
Hasford  
The Hasford prognostic score was developed in the interferon era29. It was based on the 
analysis of 908 patients and generated an algorithm based on several covariates: age, 
spleen size, blast count, platelet count, eosinophil count, and basophil count. The score was 
found to be predictive of survival in interferon-treated patients. 
Eutos 
The European leukaemia net came up with a prognostic score for CP CML patients treated 
with imatinib first line30. 2060 patients gathered from 5 national studies to make the 
“European Treatment and Outcome Study” (EUTOS) for CML in order to provide a score 
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that predicts the probability of achieving a CCyR within 18 months. The simple formula for 
calculating the new (EUTOS) score can be shortened into:  
 
Equation 1- Eutos score 
EUTOS score = (7 X basophils) + (4 X spleen size)  
 
The spleen was measured in centimetres below the costal margin and basophils as a 
percentage at baseline. A EUTOS score of > 87 indicates high risk and < 87 low risk. The 
reliability of the score could not be fully ascertained from studies published based on single 
institution experiences. For example Marin et al and Jabbour et al using patients treated at 
their respective institutions showed Sokal and Hasford prognostic indices to be superior to 
EUTOS in predicting survival outcomes31, 32. On the other hand, a study by Tiribelli et al 
showed that EUTOS score was predictive of long term survival of imatinib treated patients 
but not predictive of cytogenetic and molecular milestone achievements33. A large study by 
Hoffmann et al showed EUTOS score to be predictive of achievement of cytogenetic and 
molecular milestones as well as survival outcomes34. In the face of a number of publications 
showing both the merits and inadequacies of the EUTOS score, it is difficult for this to be 
universally acceptable as a replacement for the time tested sokal and Hasford prognostic 
scoring methods. 
I.6 Treatment: 
Historical treatment approaches: 
Arsenic has been mentioned as a possible treatment approach for cancer in Ramayana, an 
Indian epic written 1000’s of years ago. In modern age, the earliest documented attempts at 
treating CML using arsenic was reported by Heinrich Lissauer in 1865, an effective therapy 
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in the treatment of CML when 2 patients were treated35. Author Conan Doyle has mentioned 
in his works of using arsenic to treat a patient with CML. Subsequently, the discovery of X-
rays by Wilhelm Roentgen in 1895 brought a new treatment for leukaemia and results 
seemed to be similar to those produced by arsenic36. In the 1920s, splenic irradiation was 
introduced for symptomatic relief.  
Effective control of blood counts became feasible with the introduction of busulphan by 
David Galton, from London37. In 1968 he published a paper reporting that busulfan-treated 
patients lived longer than those who received radiotherapy and thereafter busulfan became 
the standard treatment for CML in the UK. The down side to busulphan was that it regularly 
rendered women infertile and men azoospermic. In those days the median survival from 
diagnosis was about 5 years. This became the standard of care until the better-tolerated 
hydroxyurea became available, probably the first intervention with a (modest) prolongation 
of survival.  
Development of treatment methodologies leading to present treatment: 
Research conducted during the 1980’s showed that allogeneic stem cell transplantation, 
although hazardous and even sometimes fatal, could if induce long term remissions and 
probably cure some patients38. Investigators at Seattle had shown that CML patients 
transplanted with marrow cells collected from their identical twins could expect a number of 
years without evidence of leukemia detectable in their body, paving the way for transplant to 
be considered the standard for eligible patients. Therefore, from the 1990’s onwards, the 
treatment of choice for all relatively young patients (i.e., under the age of 50) who presented 
in chronic phase was an allogeneic stem cell transplant (SCT)2.  
The next big treatment to arrive on the CML scene was interferon. Moshe Talpaz, at the MD 
Anderson centre in Houston pioneered the use of IFN to treat CML39, 40. Some of the 
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patients who received this treatment achieved Philadelphia chromosome negativity and a 
small number of patients who achieved this status did not relapse when the IFN was 
discontinued. Interferon was associated with modest prolongation of life when compared 
with the use of hydroxyurea. Later on, evidence from France suggested that the best 
treatment for CML patients who aren’t eligible for allografting was a combination of IFN-α 
plus cytarabine (Ara - C)41, subsequently data from Italy has refuted some of these claims42.  
It was in 1996, when Druker and colleagues described CGP57148, a highly specific 
pharmacologic inhibitor of the ABL1-tyrosine kinase that selectively suppressed the growth 
of BCR-ABL1-positive cells that CML therapy was changed43, 44. This compound, first 
renamed STI571 and then imatinib (Novartis, Basel, Switzerland) revolutionized the 
treatment of CML and set an example for the development of more potent, newer second 
and subsequent generation of tyrosine kinase inhibitors like dasatinib, nilotinib, bosutinib, 
ponatinib and radotinib.  
Current Therapies: 
Hydroxycarbamide (hydroxyurea): 
Introduced in 1972, a cell cycle–specific inhibitor of DNA synthesis became available for the 
treatment of chronic myelogenous leukaemia. It allowed rapid but transient haematologic 
control, was well tolerated, and had few side effects (nausea, vomiting, diarrhoea, mucosal 
ulcers, and skin manifestations). Hydroxyurea was given orally at 40 mg/kg daily, and doses 
are adjusted to maintain a leukocyte count of 2 to 10 cells x109/L 45. Although hydroxyurea is 
effective in controlling the white blood cell count and reduces the splenomegaly of CML, it 
does not eradicate the Ph clone. Its current role is limited to the initial normalisation of 
counts in newly diagnosed CML at doses ranging from 0.5g to 3g daily.  
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Interferon Alfa: 
The use of Interferon-α in CML has been pioneered by the MD Anderson cancer centre39, 40. 
It was introduced in the back drop of highly myelosuppressive drugs that did not lead ph 
negativity. IFN-α can not only induce Ph negativity without drastic myelosuppression, but 
there was convincing evidence that it prolongs survival by delaying the onset of the blastic 
phase CML46. Sensitive molecular analysis revealed underlying Bcr-Abl transcripts in 
patients who attained CCyR on IFN- α, showing that IFN causes a reduction in the transcript 
level rather than eliminating it altogether. IFN-α induced complete cytogenetic response in 
5% to 20% of patients. This was associated with a survival greater than 10 years. In fewer 
than 1% of patients the BCR-ABL1 transcripts became undetectable by the most sensitive 
PCR technique and many of these patients could be considered as operationally cured as 
the leukemia did not appear to relapse after prolonged discontinuation of the therapy. IFN 
was associated with significantly increased side effects with 15 to 25% of patients 
discontinuing treatment and 30% to 50% requiring dose reductions. The most common 
immediate side effects were “flu-like” symptoms including fever, shivers, myalgia, and 
tiredness. In most patients these effects wore off after a few weeks. The main 
haematological side effect was thrombocytopenia.  
Stem cell transplantation (SCT): 
Allogeneic stem cell transplant from a suitably fully matched sibling resulted in the high cure 
rates47. The possibility of obtaining fully matched sibling donor in this day and age in 
“developed” countries is about 25% to 30%. The probabilities of 5-year overall survival and 
leukemia-free survival are 60% to 80% and 55% to 70%, respectively, with a 10% to 20% 
relapse rate48. Majority of the relapses occur early and within the first three years following 
which they are rare. The initial attempts at a fully matched volunteer unrelated donor 
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transplant was associated with increased mortality and morbidity from graft vs. Host 
disease, graft failure and increased transplant related mortality. Subsequently improved 
donor selection was able to show rates of survival in the first few years to be equivalent to 
the fully matched sibling donors.  
Transplantation risk assessment:  
Although allo-SCT offers a clear benefit of providing a cure to a rather lethal condition, one 
clear disadvantage is that it is associated with a high rate of morbidity and mortality48. 
Outcome has been improved over the years by selecting those patients who are most likely 
to benefit from the procedure. The European Group for Blood and Marrow Transplantation 
(EBMT) developed a risk score system for patients with CML undergoing transplant49.  
The EBMT score is based on 5 variables: donor type, disease phase, recipient age, 
donor/recipient sex combination, and interval from diagnosis to transplantation 49. These five 
factors provide a score from 0 as lowest up to 7 as highest risk.  
Risk assessment can be further adjusted by integrating additional elements known to 
influence transplant related mortality (TRM), such as cytomegalovirus (CMV) serological-
status of the recipient, cytokine polymorphisms or the co-morbidity score50-52. Expression of 
the polycomb group gene BMI-1 was shown to reduce TRM in patients with CML53.   
A defined natural killer receptor, KIR2DS5, was shown to be associated with a higher risk for 
relapse despite allogeneic SCT54  and recently, C-reactive protein level less than 10mg/L 
(regardless of infective status) has been also shown to be an independent predictor for 
survival55.  
Graft-versus-host-disease and T-cell depletion:  
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The major causes of morbidity and mortality during SCT are infections and graft-versus-host 
disease (GVHD). Now GVHD could be prevented using a combination of methotrexate and 
cyclosporine post-transplant. This combination offers good protection without a significant 
increase in relapse56. The 1980s saw the introduction of T-cell depletion, which was effective 
in decreasing the severity and frequency of GVHD, but was associated with a higher 
frequency of graft failure57.  
Donor lymphocyte infusions 
Donor lymphocyte infusions have been remarkably successful in treating post transplant 
relapses in CML patients. Its principle relying on the evidence that donor T lymphocytes can 
exert a graft vs. Leukaemia (GvL) effect, potentially able to eradicate the residual host 
disease. In order to restore remission to transplanted patients who have relapsed, additional 
donor lymphocytes were given58. Their therapeutic principle relies on the evidence that 
donor T lymphocytes can exert a graft-versus-leukaemia effect (GVL), potentially able to 
eradicate the residual host disease58.  
Administration of DLIs can re-induce remission in 60% to 90% of patients with CML who 
underwent transplantation, and relapsed in chronic phase. The use of escalating doses in 
case of persistent disease limits the risks for GVHD59, 60. A European study showed a 69% 
5-year survival in 328 of patients who received DLI for relapsed CML61.  
DLI-related mortality was 11% and disease related mortality was 20%. Some form of GVHD 
was observed in 38% of patients. Risk factors for developing GVHD after DLI were T-cell 
dose at first DLI, time interval from transplantation to DLI, and donor type. In a time-
dependent multivariate analysis, GVHD after DLI was associated with a risk of death of 2.3-
fold compared with patients without GVHD 62. With the advent of targeted therapies like 
imatinib, stem cell transplant has been replaced as the primary option for cure.  
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Currently available targeted therapies: 
Imatinib: 
The collaboration between Druker, his colleagues and Ciba-geigy (now Novartis) resulted in 
a phenyl-aminopyrimidine molecule, then called CGP57148B, that occupied the kinase 
pocket of the BCR-ABL1 protein and blocked access to ATP, thereby preventing 
phosphorylation of any substrate44. Preclinical studies showed that the molecule was highly 
effective in blocking the tyrosine kinase activity of ABL1; the stem-cell factor receptor, c-kit; 
and the platelet-derived growth factor receptor (PDGFR) but had little effect on other 
tyrosine kinases. The addition of a benzamide group and a polar side chain enhanced the 
molecule’s efficacy against tyrosine kinases and also improved its bioavailability 
significantly43.  
The molecule was known as (STI1571) Imatinib mesylate, binds to the amino acids of the 
BCR-ABL1 tyrosine kinase ATP binding site and stabilizes the inactive, non-ATP-binding 
form of BCR-ABL1, thereby preventing tyrosine auto- phosphorylation and, in turn, 
phosphorylation of its substrates, resulting in “switching off” the downstream signalling 
pathways that promote leukaemogenesis43.  
 
 
Figure 4- Mechanism of action of imatinib 
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The excellent in vitro data led to subsequent in vivo and rapidly onto phase 1 and 2 clinical 
trials63-66. Imatinib was administered once daily and pharmacokinetics showed a half-life of 
13 to 16 hours and was fairly well tolerated with minimal side effects. In June 2000, the 
landmark IRIS phase 3 trial comparing upfront 400mg imatinib to a combination of IFN-a 
with Ara-c (cytosine arabinoside), which was considered a standard treatment at that time 
was initiated. With a median follow-up of 19 months, patients randomized to imatinib had 
significantly better results than patients treated with IFN-α plus Ara - C in all parameters 
measured, including rates of CHR (97% vs. 56%, P < 0.001), MCyR and complete 
cytogenetic responses (CCyR) (85% and 74% vs. 22% and 8%, respectively, P < 0.001), 
discontinuation of assigned therapy due to intolerance (3% vs. 31%), and progression to AP 
or BP (3% vs. 8%, P < 0.001).  
The most recent data from an 8 year follow up of IRIS trial, the estimated event free survival 
(EFS) at 8 yr was 81% and freedom from progression to AP/BP was 92%67. Estimated OS 
was 85% at 8 yr and 93% when only CML-related deaths and those prior to SCT were 
considered. Imatinib is known to be associated with a few side effects, most of which are 
mild to moderate in intensity and settle after the first few months of treatment. Most patients 
don’t require dose reduction or interruption of therapy. The main haematological side effects 
 Page 29 of 171 
are neutropenia and thrombocytopenia. The main non haematological side effects are 
fatigue, deranged LFT’s, rash, oedema (including peripheral and periorbital), muscle 
cramps, diarrhoea, nausea and musculoskeletal pain. These non haematological side 
effects sometimes tend to stay on as chronic low grade side effects. 
Nilotinib: 
Nilotinib (AMN107, Tasigna®; Novartis) is an orally bio available, rationally designed, 
derivative of imatinib designed to overcome its resistance in CML and was found to be 30-35 
times more potent than imatinib in inhibiting BCR-ABL1 in pre clinical models68, 69. In earlier 
phase I and II studies nilotinib showed good tolerability in adult patients with Ph+ CML who 
have been resistant or intolerant to at least 1 prior line of treatment68, 70. The phase III trials 
have shown that nilotinib induces deeper responses more rapidly and in more patients than 
imatinib when compared upfront in newly diagnosed patients71-73. Nilotinib has shown 
remarkable efficacy in chronic and accelerated phase of the disease but the evidence is 
lacking when it comes to its efficacy in blast transformation phase of CML. It is currently 
approved for use both in a front line setting and for subsequent lines of therapy. Whilst 
nilotinib can overcome the majority of the mutations resistant to imatinib, the T315i (gate 
keeper) mutation has proven to be resistant.  
The main side effects related to nilotinib apart from the myelosuppression is its non 
haematological side effects. The main ones are rash, pruritus, deranged LFT’s (especially 
hyperbillirubinemia), GI symptoms, cardiovascular toxicity like cardiac failure, arrhythmias, 
peripheral arterial occlusive disease and hyperglycemia especially in diabetics. Cortes et al 
showed in a study on patients who switched over to nilotinib from imatinib that there was 
very little cross intolerance amongst the different the two meaning that the side effects could 
potentially be overcome by switching TKI therapy. 
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Dasatinib: 
Dasatinib is a potent orally available ABL kinase inhibitor with 325-fold greater in vitro 
selectivity for un-mutated BCR-ABL1 than imatinib. In addition to blocking BCR-ABL1 kinase 
activity, it also inhibits a wide spectrum of other kinases, including SFKs, c-Kit, platelet-
derived growth factor-receptor (PDGFR), and ephrin-A receptor74, 75. The effectiveness of 
the early phase clinical trials brought about an FDA approval for second line use in 2006 and 
upfront in 201276, 77. The most recent update on the phase III trials show patients attaining 
molecular and cytogenetic milestones (CMR, MMR & CCyR) earlier when compared to 
standard imatinib therapy78. The various trials have so far failed to show an improvement in 
overall survival when compared to the Imatinib data. The argument for using dasatinib 
upfront is similar to nilotinib in that a greater suppression of the Bcr-Abl clone early on leads 
to fewer progressions and more patients are likely to attain the early molecular monitoring 
cut offs at 3 and 6 months.  
The side effects from dasatinib are related to its off target effects. The main side effects of 
dasatinib are pleural effusion and myelosuppression. There have been a number of reports 
with regards to pleural effusion and old age, Lymphocytosis, advanced phase of the disease 
and higher dose are thought to be its risk factors. The other side effects that have been 
reported of late include pulmonary arterial hypertension and it is not clear if it is reversible on 
stopping the drug. Some of the other side effects include fluid retention, GI disturbances 
including colitis, headache, musculoskeletal disorders, rash, and infection. 
Bosutinib: 
Bosutinib (formerly known as SKI-606; Wyeth/Pfizer, New York, New York, USA) is a dual 
ABL1/SRC TKI which, like nilotinib and dasatinib, is more potent than imatinib and offers 
activity against several imatinib resistant ABL1 mutations79. After its efficacy was 
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demonstrated in imatinib resistant patients in a second line setting, a phase III trial 
compared standard dose of 500mg bosutinib to 400mg imatinib80, 81. This trial failed to meet 
its primary end point (superiority of attainment of CCyR). There was no difference in CCyR 
rates at the end of 1 year although the trial did show earlier attainments of cytogenetic and 
molecular milestones. Treatment interruptions and dose reductions were higher in bosutinib 
treated patients on imatinib.  
The main side effects associated with bosutinib was GI toxicity in the form of diarrhoea, 
vomiting and abdominal pain. The other side effects which are common to a majority of the 
TKIs (edema, musculoskeletal pains, fatigue, elevated transaminases and 
myelosuppression) were also noted with bosutinib. 
Ponatinib: 
Ponatinib (AP24534; Ariad Pharmaceuticals, Cambridge, MA) is a novel TKI of BCR-ABL1 
with activity against all known BCR-ABL1 mutants, including T315I82. A phase I trial showed 
clear evidence of anti-leukaemia activity, with major cytogenetic responses in 46% of 
chronic-phase patients resistant to second-line tyrosine kinase inhibitors, including 67% of 
those with the T315I mutation83, 84. The Phase II trial trail data has been presented at ASH 
2012 recently and has confirmed the efficacy shown in the phase I trial in patients both 
intolerant and resistant to second generation TKIs85. Over half the patients in the trial had 
received all three approved TKIs (53%) previously. The findings showed MMR rates of 25% 
in patients with T315i mutation and 28% of patients overall had attained MMR at the end of 
9 months. The estimated probability of remaining in MMR at 6 months and 1 year is 87% 
and 84% respectively. A phase III trial comparing ponatinib at a dose of 45mg to upfront 
imatinib 400mg in newly diagnosed CP CML patients is underway.  
 Page 32 of 171 
The major side effects noted with ponatinib was myelosuppression and this was in a heavily 
pre treated population. The other major non haematological side effects included 
pancreatitis, dermatological side effects including rash, pruritus, and other constitutional 
symptoms like nausea, vomiting, fatigue and arthralgia.  
Radotinib: 
Radotinib is a novel, selective Bcr-Abl tyrosine kinase inhibitor (TKI) developed by IL-YANG 
Pharm, South Korea. Radotinib showed a good efficacy and safety profile to chronic myeloid 
leukemia (CML) in preclinical and phase 1 clinical studies. It has been approved for second 
line and beyond CP CML patients in South Korea. The interim results of a phase II trial of 
Radotinib usage in a second line setting with a median follow up of 10.5 months was 
presented at ASH 201286. The results from 77 patients who received at least 3 months of 
therapy showed fewer than half the patients (45.4%) attained a complete cytogenetic 
response and 18.2% attained a partial cytogenetic response. A phase III trial comparing 
upfront usage (300mg BD or 400mg BD of Radotinib vs. 400mg OD of imatinib) is currently 
underway. Radotinib appears to be effective in patients who have either been intolerant or 
resistant to imatinib but is not active against the T315i mutation. 
Omacetaxine: 
Omacetaxine mepesuccinate (formerly known as homoharringtonine) is a reversible inhibitor 
of protein translation. It’s activity therefore is not inhibited by the mutational status of Bcr-
Abl. There have been a number of publications over the years to support the clinical 
effectiveness of omacetaxine in CML over the last 25 to 30 years87. It fell out of favour in the 
last decade owing to the tremendous success of TKI inhibitors. Recently Cortes et al 
reported the findings of a phase II study showing the effectiveness of omacetaxine in CML 
patients bearing the T315i mutation and having had prior TKI therapies which has in a way 
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brought it back to the forefront as a possible alternative88. The CHR in this heavily pre 
treated population was 77%. The rates of the Major and complete cytogenetic responses 
were 23% and 16% respectively. This drug represents a possible alternative along with 
ponatinib for CML patients bearing the T315i mutation. The drug is given as a subcutaneous 
injection, with the induction dose of 1.25mg/m2 twice a day for 14 days in a 28 day cycle. 
Once the patients reach a CHR, they are then switched on to the maintenance cycle 
comprising 1.25mg/m2 twice a day for 7 days in a 28 day cycle. The main side effects were 
related to myelosuppression.  
I.7 Current issues in CML 
CML has been transformed in the last decade and half from a near fatal condition with 
median survival of around 3 to 5 years to well over 25 years and counting. All of this has 
been made possible with the advent of the TKI therapies from imatinib to the third 
generation ponatinib. The most recent updates from the long term follow up of the IRIS trial 
looking at the survival figures of the imatinib treated patients puts OS in excess of 93% for 
CML related deaths at 8 years67. The newer TKI’s have shown improvement in the early 
response rates compared to imatinib. Second and third generation TKI’s when used upfront 
show improved and earlier attainment of milestones like CCyR and MMR when compared to 
imatinib and is postulated to improve already excellent OS rates obtained with imatinib. The 
improved early responses have also shown lower progression to advanced phase of the 
disease and the reasoning behind it is thought to be a greater suppression of the Bcr-Abl 
clone early on. With such excellent cure rates, the focus of CML management has shifted 
from finding newer therapies to trying to improve outcomes to the existing therapies and 
improve patient experience on them.  
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Early molecular responses to TKI therapy has been shown to be predictive of excellent 
outcomes by a number of groups. Branford et al showed in 2006 from an analysis of the 
IRIS trail data that Bcr-Abl transcript numbers of less than 10% at 3 months predicts patients 
like to attain higher rates of CCyR89, 90. Subsequently Marin et al showed that a transcript cut 
of 9.84% at 3 months and 1% at 6 months are likely to identify patients at risk of poor clinical 
outcomes91. Hanfstein et al from the German collaborative group shown similar findings 
using cut offs of 10% and 1% at 3 and 6 months and that failure to attain them results in 
inferior clinical outcomes92. These results helped focus attention firmly on identifying patients 
who may do poorly using the cut offs. It was however not clear if the patients need to fail the 
3 and 6 month cut off to be predictive of poor responses or simply failing to attain the 3 
month cut would predict poor responders on its own. To answer this question we tried to 
analyse the data from patients who attended the Hammersmith hospital for management of 
their CML. 
The key to maintaining good clinical outcomes lies in good adherence to therapies over a 
long period. Patients not adhering to prescribed medications are not only confined to CML 
alone. Indeed, the problem is pervasive across chronic conditions. The average adherence 
to long term therapies according to a 2003 WHO report in diseases like asthma, diabetes, 
hypertension, and tuberculosis was only about 50% in developed countries, and possibly 
even lower in developing countries where the access to resources like healthcare is very 
variable and unpredictable.  
Adherence to TKI therapy has gained importance following a number of publications 
showing poor adherence correlating with inferior clinical outcomes like attainment of CCyR, 
MMR and CMR. The adherence to TKI therapy has been varyingly shown to be between 20 
to 100% by a number of groups. Marin et al showed that only 60% of people were 90% 
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adherent to their Tki therapy93. A similar study by Noens et al showed that only 14% of 
patients took their TKI therapy all the time94. Efficase et al showed adherence rates of 53% 
using a questionnaire based study95.  There are a number of ways to monitor adherence. 
The gold standard would be a directly monitored continuous observation of the patients 
taking the medications, a method that would be practically impossible and economically 
unviable in most healthcare settings. Marin et al showed that adherence of <90% correlated 
with failure to attain CCyR, MMR and CMR using a microelectronic monitoring device 
(MEMS)93. MEMS was a device fitted to bottle caps to record opening and closing of 
medicine containers and is considered the most practical gold standard method of 
monitoring adherence. The downside of such a method is the cost implications and the fact 
that MEMS records only the opening of the containers and the actual pill taking96, 97. The 
other methods that have been used over the years are measurement of blood levels. 
Imatinib blood levels have been shown to be an useful method of estimation of recent 
imatinib dosage and was initially developed to test the appropriateness of the dosage for a 
particular patient98. The levels are done in a clinic prior to seeing a clinician. Apart from the 
information that imatinib was recently taken by the patient it does not shed any more light on 
the long term adherence of the drug similar to HbA1c measurement of glucose in diabetic 
patients. The other method would be pill counting which is labour intensive and does not 
correlate with actual everyday pill taking rather than just long time estimation96. Medication 
possession ratios and pharmacy refills have also been used in some studies to determine 
adherence to TKI therapies. A lot of these measures are practically difficult to be used 
continuously in a clinic setting to monitor adherence behaviour over a period of time. In this 
background we tried to study the practical feasibility of using simple self reported measures 
of adherence and correlate them with clinical outcomes. If successful, they could become a 
useful tool to study a pattern of adherence over a period of time. There have been various 
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possible theories that have been put forward as to the reasons for non adherence to TKI 
therapies99. In a cancer setting with patients on oral medications it has been postulated that 
patient related factors like daily routine, communication with the clinical team, anxiety, 
depression, beliefs about medicines could play in important role in determining a patients 
behaviour to taking the medications long term95, 100. We have tried to study the impact of 
such factors on self reported adherence and clinical outcomes using a questionnaire based 
study. The eventual goal would be to try to generate surrogate markers of adherence based 
on patient related factors which could be used to monitor adherence as the self reported 
adherence questionnaire involves direct questions pertaining to adherence.  
Compliance to TKI therapy can depend on a number of factors including tolerability. All TKI 
therapies from imatinib to the recent ponatinib have side effects even though they are fairly 
well tolerated. Side effects can be one of the main reasons for treatment interruptions and 
possible inferior clinical outcomes96. Chronic low grade side effects often persist for a long 
term, not necessarily leading to treatment interruptions, but can often end up with 
interference to the quality of life of the patient. A lot of the side effects are thought to be a 
class effect of the particular type of TKI in the sense that all therapies can give rise to the 
same side effect of varying degrees. In this background we were interested in seeing if 
changing TKI on the basis of their side effect profile would be a helpful measure to not only 
alleviate the low grade side effects but also improve upon their molecular responses further. 
We tried to study the effect of changing TKI therapy after patients have attained a CCyR to 
assess their response to a change. If it showed good results, this could be a way forward to 
minimise or eliminate the chronic low grade side effects with no adverse impact on the 
clinical responses.  
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I.8 MD Project 
The main essence of my MD was to optimise treatment for chronic myeloid leukaemia. I 
have tried to achieve optimisation through various stratergies. The first is to optimise early 
molecular monitoring approaches to identify poor responders. We have tried to identify early 
time points that can help to prognosticate patients better and identify poor responders 
earlier. This can help to intervene early to possibly alter the clinical course. The second 
strategy is to optimise adherence. We wish to devise simple and practical means to identify 
non adherence using self reported measures and correlate them with clinical responses. We 
also wish to identify reasons for non adherence and develop surrogate markers for non 
adherence using a questionnaire based study. The third strategy is to optimise intolerance. 
This involves a study trying to change TKI therapy to ameliorate chronic low grade side 
effects to improve intolerance.   
MD title: Optimisation of CML therapy 
1. Optimisation of early molecular monitoring, by identifying cut offs to predict poor responders 
2. Optimisation of adherence,  to correlate self reported adherence with outcomes and identify 
reasons for non adherence to TKI therapy 
3. Optimisation of intolerance by changing TKI therapies to overcome chronic low grade side 
effects 
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Chapter II. Methods 
II.1 Database 
There were two databases used for the purposes of my thesis. One was a database that 
was maintained in the haematology department at the Hammersmith hospital with records of 
all patients treated at the centre and the second database was created newly for the 
questionnaire based study.  
First database for CML patients was an access database comprising three tables. Table I 
contains the basic demographic data, details of diagnosis and of treatment and response 
before starting treatment with imatinib. Table II contains descriptive data applicable at the 
actual time of starting imatinib. Tables I and II both contain a register for each patient. Table 
III contains the imatinib data, where each patient is represented by an unlimited number of 
registers each showing the situation of the patient at a given time point (visit). All three 
tables are by the patient identifier number (N). The variables and codes included in the 
database are shown in Appendix I.  
The second database was designed to capture the information from the questionnaire study. 
It was an access database that contained 2 tables. Table 1 contained all the patient entered 
data including their diagnosis, date, treatments and answers to questions regarding 
adherence and factors thought to influence adherence. The second table included 
information that the clinician entered information pertaining to the treatment, line of therapy, 
PCR results and the dates. 
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II.2 Hammersmith Study 
II.2.1 Patients and methods 
Patients  
For our analyses, we included a total of 274 patients with Ph +ve, BCR-ABL1 +ve CML 
patients in chronic phase who were treated with first line imatinib at the Hammersmith 
Hospital. These patients included: patients enrolled in current clinical trials; patients who are 
on follow up from older trials; and newly diagnosed patients who started imatinib therapy 
within 6 months of diagnosis as imatinib became available within the NHS (non trial 
patients).  
TKI administration  
Imatinib:  
Imatinib was prescribed to patients at a dose of 400 mg orally daily. The dose was adjusted 
according to tolerance and response: it was reduced in the presence of grades 3-4 toxicity208 
and hematopoietic growth factors were administered with the aim of maintaining imatinib 
higher than 300 mg/d.  
Dose escalation for patients on imatinib who failed to achieve a complete haematologic 
response at 3 months or at least a minor cytogenetic response (defined as between 36 to 
65% Ph-positive metaphases) at 12 months were applied as in the phase II trial or the IRIS 
study, but as more evidence accumulated, the criteria evolved and resembled the 
subsequent recommendations from the European Leukaemia-Net and NCCN. The patients 
were switched to a second generation TKI (nilotinib, dasatinib or bosutinib) either due to 
resistance or intolerance. 
Dasatinib & Nilotinib:  
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Dasatinib was administered at a dose of either 70mg every 12 hours (twice daily) or 100mg 
once daily. Nilotinib was given at a dose of 400mg twice daily in patients intolerant or 
resistant to a previous TKI and in a dose of 300mgBD for upfront management of newly 
diagnosed patients. Doses were adjusted according to tolerance. 
Bosutinib:  
Bosutinib was prescribed to some of our patients who are participating in phase III clinical 
trials and was also used outside them. Bosutinib was given in a dose of 500mg/day, which 
was also adjusted according to tolerance.  
Definitions and monitoring of responses  
Chronic phase (CP) and complete hematologic response (CHR) are defined by standard 
criteria. Bone marrow morphology and cytogenetics are assessed at diagnosis and then 
every 3 months, until patients achieve CCyR using Giemsa banding. Thereafter, patients are 
monitored by real-time quantitative polymerase chain reaction (RQ-PCR) and annual bone 
marrow examinations.  
A complete cytogenetic response (CCyR) is defined by the failure to detect any Philadelphia 
chromosome (Ph)-positive metaphases in two consecutive bone marrow examinations with 
a minimum of 20 metaphases examined. A partial cytogenetic response (PCyR) is defined 
as a decrease in the proportion of Ph-positive metaphases to between 1 and 35%, while a 
major cytogenetic response (MCyR) is defined by combining the number of complete and 
partial cytogenetic responses (<35% Ph +ve metaphases), and a minor cytogenetic 
response (MiCyR) is defined as a decrease in the proportion of Ph +ve metaphases to 
between 35 and 95%.   
Measurement of BCR-ABL1 transcripts  
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BCR-ABL1 transcripts were quantitated by RQ-PCR using the TaqMan Real-time PCR 
apparatus (Perkin-Elmer, Wellesley MA, USA) in the Minimal Residual Disease (MRD) 
Laboratory of the Hammersmith Hospital. BCR-ABL1 transcripts and ABL1 transcripts 
selected as internal control were quantified separately. Results were expressed as percent 
ratios relative to an ABL1 internal control with original laboratory values converted to the 
international scale{Hughes, 2006 #117}. Peripheral blood cellular RNA was reverse 
transcribed to cDNA using standard molecular biology techniques{Cross, 2008 #140}. The 
cDNA was then subjected to 50 cycles of analysis using the ABI 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA) and TaqMan Universal Master Mix in 
accordance with the manufacturer’s instructions in a final reaction volume of 25 µl. Probes 
and primers were designed using the Primer Express software (Applied Biosystems) to 
detect e13a2 and e14a2 junctions in a single reaction by RQ-PCR.  
Probes were designed for BCR-ABL1 (-cccttcagcggccagtagcatctga-TAMRA) and ABL1 
(tgcttctgatggcaagctctacgtctcct-TAMRA) and dual labelled with 6-carboxyfluorescein (FAM) 
and 6-carboxy-tetramethyl-rhodamine (TAMRA). The primers used in Q-PCR were: BCR-
ABL1 forward primer: 5’-tccgctgaccatcaayaagga-3’; BCR-ABL1 reverse primer: 5’-
cactcagaccctgaggctcaa-3’; ABL1 forward primer: 5’-gatacgaagggagggtgtacca-3’: ABL1 
reverse primer: 5’ctcggccagggtgttgaa-3’. The probe and primer concentrations for ABL1 
mRNA quantification were 200 nM and 300 nM respectively and 3 µl of cDNA. The BCR-
ABL1 mRNA levels were measured using 100 nM of probe and 300 nM of each primer with 
5 µl of cDNA.  
BCR-ABL1 and ABL1 copy numbers were calculated by comparison with the standard curve 
generated using serial dilutions of linearized pNC210/G plasmid, containing the BCR-ABL1 
insert described previously. The sensitivity in our laboratory of quantitative RQ-PCR is equal 
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to that of conventional nested PCR, i.e. 1x10-5, so the failure to detect any BCR-ABL1 
transcripts using RQ-PCR represents a reduction of at least 5 logs.  
Detection of tyrosine kinase mutations  
Direct Sequencing  
The BCR-ABL1 amplicon from each subject in the study was subjected to nested primer 
PCR using primers NTPB+ and NTPE- to generate an 863-bp fragment containing the entire 
BCR-ABL1 kinase domain.  
An aliquot of the PCR products was electrophoresed through 2.0 % agarose gel; if a single 
amplicon was observed the remaining PCR products were purified using Magna-PCR clean 
up kit in accordance with the manufacturer’s instructions (DRI, UK). Otherwise the PCR 
fragment containing the Abl kinase domain was isolated using commercially available gel 
purification kit (Qiagen, UK) as recommended by the manufacturer. The purified amplicons 
were then subjected to Sanger’s dideoxy chain termination reaction using a Big-Dye ABI 310 
sequencer (Applied Biosystems, Foster City, USA). In each case the sequence obtained 
was compared with the published ABL1 type 1a sequence, GenBank M14752, using BLAST 
2 software. All observed base substitutions were confirmed by sequencing the 
complementary strand.  
Statistical analysis  
The data was analysed using the statistical package SPSS statistics 20.0 (August 2012, 
SPSS Inc., Chicago, Illinois). Data was obtained from a database maintained in our 
department comprising of all patients with CML seen at the Hammersmith hospital since 
2002. Probabilities of OS, PFS and event-free survival (EFS) were calculated using the 
Kaplan-Meier method. Events were defined as loss of a CCyR or CHR, progression to 
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advanced phase, death or imatinib discontinuation. Univariate analyses to calculate the 
probabilities of cytogenetic and molecular responses were done using the cumulative 
incidence (CI) procedure. The probabilities were compared using the log rank test or a Cox 
regression model. Variables found to be significant at p < 0.1 level was entered in the 
multivariate analysis unless otherwise mentioned in relevant sections.  
 
II.3 Questionnaire study 
Ethics and approval 
The study was approved by London wandsworth research ethics committee and also by the 
institutional review board. All participants provided written informed consent in accordance 
with the declaration of Helsinki. 
Patients 
Patients: 
Two hundred and ninety six patients with CML in 1st chronic phase (CP) were recruited 
during out-patient appointments from six hospitals (Hammersmith Hospital, Nottingham 
University Hospital, Royal Liverpool Hospital, Gartnavel General Hospital, Monklands and 
Hairmyers Hospitals) across the UK between September 2011 and January 2013. Two 
patients refused to take part.  
The patients were all approached by the one of the members of the healthcare team in their 
routine outpatient clinic appointments. The patients all had to be on a TKI therapy for chronic 
phase chronic myeloid leukaemia and had to have been on it for atleast 3 months. Patients 
were given an information leaflet and the nature of the study explained. Patients who agreed 
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to take part were then made to sign an informed consent. They were then handed a pack 
containing the questionnaire, a copy of their signed consent form and an opaque envelope. 
The completed questionnaires were to be returned in the opaque envelope. There were no 
patient identifying details either on the questionnaire or on the envelope (anonymously 
coded). All the completed questionnaires were then centrally entered into a database.  A 
clinical info sheet was to be parallelly completed by the treating physician.    
The patient’s characteristics are presented in table 3.  
Patient demographics: 
The median age of the patients who answered the questionnaire was 58 years (range 18-90 
years). Majority of the patients had their CML discovered in between 2000 and 2010. Sixty 
six percent of patients received TKI therapy as their first line treatment with or without 
hydroxycarbamide whilst the remainder had prior interferon therapy. For a third of the 
patients their CML tablets were their only pills and nearly 28% of patients took an additional 
5 tablets along with their CML medications. Eighty five percent of patients were british with 
another 5% being non british caucasians with the remainder of patients being either Asians 
or Afro Caribbeans. A third of the patients worked full time and another third was retired with 
students accounting for 3.1% of the study population. The median income of the patients 
was between 25,000 to 35,000£ with nearly 28% of them earning below 15,000£.  
II.4 Questionnaire 
The questionnaire based study had its origins from previous studies on adherence by Marin 
et al and Eliasson et al. The rationale for the questionnaire was to device simple measures 
to predict adherence. One way was to have self reported measures that have been used in 
other settings and the other to develop surrogate measures that correlate well with self 
reported adherence measures. The questionnaire was devised with significant input from 
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psychologists as self reported measures are highly subjective and a slight twist in the nature 
of the questioning could make it unsuitable for clinical applications. The other part of the 
questionnaire included questions pertaining to everyday life and routine of the patients to 
derive surrogates to predict adherence. 
The questionnaire is divided into 12 sections (described in detail below and also a copy of 
the questionnaire is included in the supplement section). The first section collects patient’s 
details on current and previous treatments, number of tablets and other medications. 
Section 2 to section  
II.4.1 Patient related factors: 
This questionnaire includes a range of questions related to factors that appear to be related 
to adherence in CML patients. The questionnaire is mainly based on findings from the two 
previous adherence studies (Marin 2010; Eliasson 2010). The questionnaire includes 
questions related to medication management strategies such as daily routines and the use 
of reminders, doctor patient communication, usage of internet and support services and 
patients’ understanding of the illness and treatment (included in the appendix, described 
below and table w). The questionnaire also tries to understand patient’s beliefs about their 
medications using a BMQ questionnaire. There are 2 sections devoted to understanding 
emotive issues such as anxiety and depression among patients using the validated HADS 
scale. Quality of life among CML patients on TKI therapy will be calculated using the FACT-
G questionnaire which comprises of 27 questions. 
Section 1: Patient information 
This section collected information from patients and included their year of birth, date of 
diagnosis, TKI therapies, their date of commencement, dosage and other pills that they take. 
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Section 2: Daily routines 
The section had 5 questions pertaining to daily routine (table 5 & supplement section). The 5 
questions all had 5 possible answers (1-strongly agree, 2-agree, 3-unsure, 4-disagree and 
5-strongly disagree).  
Section 3: Communication with the physician: 
Communication section included 7 questions (table 6) that looked into the communication 
between the patient and the treating physician. It aimed to analyse the level of 
communication and to see if it predicted for better adherence to TKI therapy and aso to see 
if they predicted for clinical outcomes.  
Section 4: Internet and support networks 
This section had 5 questions (table 7) looking into whether patients used internet to research 
about their disease and if support services like CML forums or psychologists were used by 
the CML patients. Each question as before had 5 possible answers ranging from 1-strongly 
agree, 2-agree, 3-unsure, 4-disagree to 5-strongly disagree. This was to see if better access 
to information and accessory facilities had a bearing on adherence. 
Section 5: taking the medicine 
It included thirteen questions (table 8) that captured information relating to patients taking 
their medications. The questions ranged from how difficult was it to remove the tablets from 
its package to swallowing them. There were a few questions pertaining to adherence and if 
patients took their tablets regularly, missed them on occasions and if they were adequately 
guided on how to take their medicines appropriately. The answers as in the sections above 
ranged from strongly agree to strongly disagree. 
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Section 6: Nilotinib usage 
The section included 6 questions exclusively pertaining to nilotinib usage. The questions 
were intended to see if fasting and twice daily dosing of nilotinib had a detrimental effect on 
adherence and to see if it affected outcomes.  
Section 8: Beliefs about medicines (BMQ questionnaire) 
Patients’ beliefs about the prescribed treatment have been shown to be associated with and 
predict intentional nonadherence in other chronic illness groups (Clifford 2008). Beliefs 
about medicines questionnaire (BMQ – section 8) was used to assess the patients’ 
treatment beliefs. The BMQ is a 10 item questionnaire assessing the cognitive 
representation of medication. The BMQ comprises two sub-scales: Necessity scale 
assesses patients' beliefs about their personal need for the medicine and how important the 
medicine is in maintaining their health now and in the future. Concerns scale assesses 
perceptions of the potential negative consequences of taking the medicine including 
concerns related to beliefs about long-term effects, dependence and other disruptive effects. 
Each item of the BMQ scales is scored on a 5-point Likert-type scale ranging from 
1 = strongly agree to 5 = strongly disagree. Specific-Necessity and Specific-Concerns scales 
have 5 items and scores range from 5 to 25.  
Scores obtained for the individual items within each scale are summed to give a scale score 
(necessity scale and concerns scale). Higher Necessity scores represent stronger 
perceptions of personal need for the medication to maintain health now and in the future. 
Higher Concerns scores represent stronger concerns about the potential negative effects of 
the medication.  
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A necessity concerns differential is calculated subtracting the necessity scores from 
concerns and the range obtained could vary from -20 to 20. A negative score represents 
concerns and a positive score leans towards necessity. The necessity and concerns scores 
are analysed as a continuous variable to see if they predict for adherence (also type of non 
adherence), response, relationship to anxiety and depression. Similar analysis is repeated 
using the necessity concerns differential. Here the necessity concerns differential is coded 
as 1 or 0 representing concerns and necessity respectively [score from -20 to 0 coded as 
‘’1’’ (concerns) and 1 to 20 coded as ‘’0’’ (necessity)]. This categorical variable is then used 
to predict for adherence, clinical response and relationship to anxiety and depression.  
(Section 9) Measures of adherence 
Adherence was measured by four self-report measures  
1. The visual analogue scale (VAS) 
The patients estimate their adherence levels by placing a cross on a line. The VAS has 
previously been validated in chronic conditions like HIV and has been used in CML 
research97, 101, 102. VAS is a single question asking patients to estimate their adherence to 
TKI to determine a numerical value of adherence on a visually coded scale. Patients were 
asked to mark what they thought was their average adherence to TKI during the last 7 days 
on a 12 cm scale. Each cm corresponds to an adherence of 10% (0 to 120%). We used a 
12cm scale instead of the typical 10cm scale to be able to capture over-adherence. The 
adherence vaues obtained are a continuous variable. They would be analysed as such and 
also be categorised to enable its usage in logistic regression. The VAS adherence scores 
were categorised into 4 categories (<80%, 81-90%, 91-98% and >100%) as a categorical 
variable. 
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2. Haynes et al question: 
It involved asking patients about the number of tablets or capsules they have missed in the 
last 7 days103, 104. The answer is numerical estimate of the missed doses in total for the last 
7 days. The aim is to try and correlate the number of missed doses with clinical outcomes. 
We also categorised the missed doses into 4 categories (No missed doses, 1 missed dose, 
2 missed doses and ≥ 3 missed doses. We compared the missed doses both as a 
continuous variable and as a categorical variable to predict clinical outcomes.  
3. Lu’s adherence scale 
The scale originally included 3 questions105. The first two questions were likert scales asking 
patients the frequency with which they took their CML medications in the last 7 days and 
their ability to take all CML medicines as prescribed in the last 7 days). The responses 
involved 6 possible options which were codified from 0% to 100% at intervals of 20% (0, 
20,40,60,80 and 100). The third question asked patients the % of time they have been 
adherent to their TKI in the last 7 days and this was to be given as a verbal estimate and 
answers ranged from 0 to 100%. The mean of the 3 answers was calculated as the measure 
of adherence.  We categorised Lu’s adherence measure into 4 categories (<80%, 81 to 
90%, 91 to 98% and >98%) as a categorical variable. The adherence was analysed both as 
a continuous and categorical variable to predict clinical outcomes. 
Previous research has shown respondents find it difficult to estimate percentages verbally 
using the original Lu question; hence this question was changed to the visual analogue 
scale described above whereby patients could answer on a visual scale. We have referred 
to this adapted Lu’s scale as Lu’s in our study.    
5. Diagnostic adherence to medicines scale (DAMS): 
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DAMS scale comprises of a set of 4 questions106. They not only detect non adherence, but 
also aim to distinguish between intentional and unintentional nonadherence. The first 
question is essentially a modification of the question by Haynes et al. The question asks 
patients to provide a numerical value of the tablets or capsules missed in the last 7 days. 
The actual tablets taken in the last 7 days is then derived by subtracting the missed doses 
from the prescribed dose. Question 2 seeks to identify the type of non-adherence 
(intentionally versus unintentionally missing doses) by asking patients to mention a reason 
for missing tablets or capsules in the last 7 days. Question three involves asking patients to 
estimate the number of extra tablets or capsules of the medication they have taken in 
addition to their usual dose in the last 7 days and this is meant to assess overuse of 
medication. Question 4 seeks to identify whether this overuse of medication was intentional 
or unintentional by again asking patients to specify a reason.  
Section 10: FACT-G (Functional Assessment of Cancer Therapy-General) : QOL 
Quality of life will be collected using the FACT-G (Supplement section), a validated quality of 
life questionnaire107, 108. FACT-G comprises of 27 questions divided into four primary Quality 
of life domains: Physical Well-Being (PWB) (7 questions), Social/Family Well-Being (SWB) 
(7 questions), Emotional Well-Being (EWB) (6 questions), and Functional Well-Being (FWB) 
(7 questions). All four domains are to be scored simultaneously. There are 5 possible 
answers to all the 27 questions, scored on a 5-point Likert-type scale from 0 (not at all), 1(a 
little bit), 2 (some what), 3 (quite a bit) and 4(very much). The responses to all the 27 
questions are summed up (the negatively worded questions are coded in the reverse). In 
cases where individual questions are skipped, scores are prorated using the average of the 
other answers in the scale. The total FACT-G score is obtained by summing individual 
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subscale scores (PWB + EWB + SWB + FWB). The higher the FACT-G score better is the 
quality of life. 
Section 11: Hospital Anxiety and Depression Scale 
The patients’ level of anxiety and depression will be assessed using the Hospital Anxiety 
and Depression Scale (HADS)109 (supplement section). The HADS is a validated and widely 
used scale for assessing anxiety and depression in patients. HADS comprises of fourteen 
items of which 7 of the items relate to anxiety and seven relate to depression. All the 14 
questions have 4 possible answers, scored using a likert type scale. Each item on the 
questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 
for either anxiety or depression. A cut off point of 8 identifies anxiety or depression. The 
anxiety and depression scores are also categorised as 0 and 1. The anxiety and depression 
scores as both a continuous variable and categorical variable is then analysed to look for 
relationships with adherence and clinical outcomes. 
Section 12: Patient demographics 
Various patient demographic data were captured in this section ranging from their 
educational background, employment status, socioeconomic status and affordability to take 
their medicines if it was not provided free of charge. 
II.5 Statistical methods: 
The data was analysed using the statistical package SPSS statistics 20.0 (August 2012, 
SPSS Inc., Chicago, Illinois). The data collected from the questionnaire study was used in 
the analysis. The statistical methodology used for the individual analysis has been described 
in detail in the chapters (4, 5 and 6). P values were 2 sided and 95% confidence interval was 
used in the statistical analysis. 
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Chapter III. Importance of early molecular responses 
III.1 Introduction 
Various clinical trials have shown that second generation tyrosine kinase inhibitors (2G-
TKIs) such as nilotinib and dasatinib induce higher rates of early complete cytogenetic 
response (CCyR) and deeper molecular responses than imatinib110, 111. On the other hand 
imatinib has clear advantages over the 2G-TKIs such as the facts that we have more than 
thirteen years of experience using this drug and that its side effect profile is well 
understood112. Moreover imatinib is likely to become much cheaper when the patent expires 
as it does soon in most countries. For these reasons there is an increasing interest in 
developing strategies that allow one to identify as early as possible those patients who are 
not going to respond optimally to imatinib, so that they can be offered 2G-TKI. These 
strategies are often referred to as ‘early intervention’ strategies. Strategies for early 
intervention may also be applied to patients treated with upfront 2G-TKI, but then the best 
alternative therapy is far from clear. 
Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 
months after starting TKI therapy strongly predicts for achievement of cytogenetic and 
molecular responses as well as for progression–free survival (PFS) and overall survival 
(OS)78, 91, 92, 113-115. Marin et al has shown that CML patients treated with imatinib who at 3 
months have a transcript level lower than 9.8% on the international scale or at 6 months 
lower than 1.67% have a better OS, PFS and higher CI of attainment of cytogenetic and 
molecular milestones compared to patients who fail to attain them91. Hanfstein et al has 
showed that patients with Bcr-Abl transcripts <10% at 3 months have a better OS compared 
to patients >10% and similarly patients with transcripts less than 1% at 6 months fare better 
than patients who fail to attain them92. We have also shown that similar results are evident in 
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2G-TKI dasatinib treated patients with a transcript level lower than 10% at 3 months fare 
significantly better than those with higher levels78. Similarly Branford et al showed that 
patients with transcripts ≤ 10% at 3 months on nilotinib had higher cumulative incidence of 
CCyR by 24 months than patients with transcripts of > 10% (53% v 16%, p<0.001)116. We 
have also shown that the molecular assessment made at 3 months on imatinib therapy is a 
better predictor of prognosis than transcript numbers assessed at 6 months or 12 months91. 
Here we investigated whether it is possible to improve the prognostic accuracy of early 
measurement of the transcript level by combining the 3- and 6-month results. 
III.2 Methods 
III.2.1 Patients  
For this analysis we used 3 populations of newly diagnosed CML in CP patients. The first 
sets of 274 patients were seen at our institution as described in the methods section 
(chapter 2). They were all CP CML patients treated with imatinib 400 mg daily first line. The 
median follow-up was 69 months (range 17–131). During follow-up 118 patients 
discontinued imatinib and received nilotinib (n=37), dasatinib (n=72) or an allogeneic stem 
cell transplant (n=9).  
The second patient cohort was a validation sample of 95 patients also treated with imatinib 
first line at the Royal Liverpool University Hospital. The third patient group was 142 patients 
treated with dasatinib 100 mg daily as first line therapy in the  SPIRIT 2 study between 
August 2008 and September 2011 (ClinicalTrials.gov Identifier:  NCT01460693). SPIRIT 2 
trial is a phase 3 study in which newly diagnosed CML patients in chronic phase are 
randomly allocated to receive either imatinib 400 mg daily or dasatinib 100 mg daily. The 
median follow-up was 18.2 months (range, 12-35 months).  Patients in all three cohorts gave 
written informed consent for their data to be used in this analysis.  
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Methods: 
This is a retrospective analysis of the data. We have tried to combine the BCR-PCR values 
from the patients at various time points (3 and 6 months) to see if they combine to give a 
better predictor of poor responders. We have tried to identify patients who achieved both 
milestones of 9.84% at 3 months and 1.67% at 6 months and patients who failed to achieve 
both. The other 2 subgroups consisted of patients who attained the 3 month milestone of 
9.84% but failed the 6 month cut off of 1.67% and also patients who failed the 3 month but 
attained the 6 month milestone. In this way we had 4 groups of patients and we tried to 
analyse overall survival (OS), cumulative incidence of CCyR and attainment of Complete 
molecular responses as described below. 
Statistical analysis: 
The data was analysed using the statistical package SPSS statistics 20.0 (August 2012, 
SPSS Inc., Chicago, Illinois). Probability of OS was calculated using the Kaplan meier 
method. We used standard definitions of CCyR and complete molecular response (CMR). 
Univariate analyses to calculate the probabilities of cytogenetic and molecular responses 
were done using the cumulative incidence (CI) procedure. P values were 2 sided.  
III.3 Results: 
We classified 274 patients, treated at Hammersmith Hospital according to their transcript 
levels. We used as a cut off the previously identified and validated transcript levels that 
optimally predict for OS at 3-months (lower or higher than 9.8%) and 6-months (lower or 
higher than 1.67%).  
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III.3.1 Overall survival at 8 years: 
One hundred and eighty one patients (66%) had low transcripts both at 3 (<9.8%) and 6 
(<1.67%) months; these patients had an excellent overall survival of 93.5% at 8 years 
(Figure 5). Fifty seven patients (21%) who had high transcript levels on both occasions (3 
and 6 months); these patients had an outcome significantly worse than those with lower 
transcripts at both time points, with an OS of 55.6% (p<0.0001 when comparing the survival 
outcomes for the two groups).   
      
Figure 5- Overall survival at 8 years 
 
8 year probability of OS. The 181 (66%) imatinib-treated patients with low transcript numbers both at 3 (<9.8%) and at 6 
months (<1.67%) had an OS of 93.5% and constitute the reference category for this analysis (group A). The 57 (21%) 
patients who had high transcript levels on both occasions (group B) had an OS of 55.6% (p<0.001). The 30 (11%) patients 
with low transcript levels at 3 months but high transcript levels at 6 months (group C) had a OS of 92.4% (p=0.78). The 6 
patients (2%) who had high transcript levels at 3 months but low levels at 6 months (group D) had OS= 83.3% (p=0.23). 
The p value for the comparisons between groups B and C was p=0.004 and between groups B and D was p=0.39.  
 
Thirty (11%) patients had low transcript levels at 3-months but high transcript levels at 6-
months; these patients had a prognosis similar to the patients with low transcripts at both 
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time points with an OS of 92.4% (p=0.78 when compared with patients who attained both cut 
offs, p=0.004 when compared to patients who failed both time paints). Only 6 patients (2%) 
had high transcript levels at 3-months but low levels at 6-months; these patients had an 
outcome similar to the patients with high transcript levels at both two time points with an OS 
of 83.3% (p=0.39).  
III.3.2 Cumulative incidence of CCyR at 8 years 
The patients who attained a transcript cut off of 9.8% at 3 months and 1.67% at 6 months 
(66%, 181 patients) had a 100% CI of attainment of CCyR, whereas the CI of CCyR was 
14.9% in the patients (21%, 57 patients) who failed to attain both the cut offs at 3 and 6 
months (p<0.001) (figure 6). 
  
Figure 6- CI of attainment of CCyR at 8 years 
 
8 years CI of CCyR for patients who attained both cut offs, failed both time points, attained 3 and failed 6 and failed 3 but attained 
6 was 100%, 14.9% (p<0.001), 99.5% (p=0.001) and 33.3% (p<0.001).  
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In the patients who achieved the cut off at 3 months, but failed the 6 month cut off (11%, 30 
patients), the CI of attainment of CCyR was 99.5% (p<0.001 when compared to the patients 
who failed both milestones). However the kinetics of attainment of CCyR was slower in the 
group that failed 6 month cut off after attaining the 3 month milestone as compared to the 
group that attained both. The median time to attainment of CCyR between the two groups 
was 6 months for the group that attained both milestones as compared to 16 months for the 
group that failed the 6 month milestone (p<0.001).  
Finally the patients who failed the 3 month cut off but attained the 6 month milestone (2%, 6 
patients), the CI of attainment of CCyR was 33.3% (p<0.001). The difference in attainment 
of CCyR between patients who attained 6 month milestone and failed the 3 month was no 
different to the patients who failed both milestones (p=0.09). 
III.3.3 Complete molecular response: 
We have previously identified cut offs in the 3- and 6-month transcript levels that predict with 
maximal sensitivity and specificity for the achievement of CMR, namely 0.61% and 0.21% 
respectively. We therefore wanted to investigate whether it was possible to improve the 
predictive value of the 3-month assessment by combining the 3- and 6-month results in 
patients who started treatment with imatinib (Figure 7).  
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Figure 7- CI of CMR at 8 years 
 
8 year CI of CMR:  Thirty four (13%) patients had low transcripts both at 3 and 6 months the 8-year CI of CMR was 75.5%. The CI of CMR for the six 
(2%) patients who had low transcript levels at 3 month but high levels at 6 months was CI=100%, p=0.8. The 193 (70.5%) patients who had high 
transcript levels on both occasions had a CI of CMR of 1.25 (p<0.001) and the 40 (14.5%) patients who had high transcript level at 3 months but low 
a 6 months had a CI of CMR of 3.6% (p<0.001). 
 
We classified the patients using these cut-offs. Thirty four (13%) patients had low transcripts 
both at 3 and 6-months; these had a very high probability of achieving CMR (75.5%). Six 
patients (2%) with low transcript levels at 3 months but high at 6 months also had a high 
probability of achieving CMR (100%, p=0.8). On the other hand both the 193 patients 
(70.5%) who had high transcript levels on both occasions and the 14.5% patients who had 
high transcript level at 3 months but low levels 6 months had a very low probability of 
achieving a CMR at 1.25% (p<0.001) and 3.6% (p<0.001) respectively .  
Validation cohort 1: 
We validated our results by classifying the 95 patients treated with imatinib at the Royal 
Liverpool University Hospital according to their transcript levels at 3 and 6 months. As with 
our study patients, patients who met the 3-months landmark but who failed the 6-month 
landmark (n=9) had OS, PFS and CI of CCyR and CMR similar to those of patients who met 
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both landmarks (n=45), and patients who failed the 3-month landmark but who met the 6-
month one (n=6) had OS, PFS and CI of CCyR and CMR similar to patients who failed both 
landmarks (n=34). 
Second validation cohort using 2G-TKI dasatinib 
We also investigated whether it was possible to improve the prognostic accuracy of early 
transcript measurements for patients who started treatment with dasatinib. We classified the 
patients according to transcript level at 3 months (lower or higher than 10%) and six months 
(lower and higher than 1%). As with imatinib, the 6-month transcript level did not improve the 
predictive power of the 3-month measurement (Table 1). Patients with a low transcript level 
on both occasions (86.3%) had a very high CI of CCyR. Patients with a high transcript level 
at both occasions (7%) fared poorly. As with imatinib the patients (10.9%) who had low 
transcript at 3 months and high transcripts at 6 also fared well but the kinetic of the response 
was significantly slower. Only one patient had high transcript levels at 3 months and low 
levels at 6 months.    
  Table 1- 2 year CI of CCyR and MR 4.5 in dasatinib treated patients 
 
Transcript ratio n (%) CI of CCyR CI of MR4.5 
3 months 6 months  p<0.001 p<0.001 
<10% <1% 104 (81.3) 100 52.9 
<10% >1% 14 (10.6) 86.9 0 
>10% <1% 1 (0.8) - - 
>10% >1% 9 (7%) 55.0 0 
Table 1: 2-year CI of CCyR and MR4.5 in 128 patients treated with dasatinib as first line therapy according to the BCR-ABL1 
transcript level at 3 (higher or lower than 10%) and 6 (higher or lower than 1%) months. 
 
III.4 Discussion: 
In summary the measurement of the transcript levels at 6 months adds very little prognostic 
discrimination to the measurement already taken at 3 months for patients who started 
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treatment with either imatinib or dasatinib. With both drugs the patients who met the 3-month 
landmark but failed the 6-month landmark had outcomes similar to the patients who 
achieved both milestones. On the other hand the patients who failed the first landmark at 3 
months do not seem to be “rescued” by the fact that they achieved the 6-month landmark, 
although this group is too small to be sure of this conclusion and clinical decisions in this 
group of patients should be made with caution. It is possible that the prognosis for patients 
starting TKI can be established accurately by assessing the transcript level just at 3 months. 
This means that strategies for early intervention can be based with confidence on decisions 
taken at this time point.   
One of the possible discussion points using the early molecular monitoring is whether 
changing therapy on the basis of a 3 month failure will alter the outcome. To argue against 
the merits and demerits of changing TKI on the basis of a 3 month transcripts level, one has 
to take into account if the patients who fail the 3 month cut off represent an inherently poor 
risk CML patient cohort who may do badly irrespective of a change in TKI therapy. It 
remains to be validated in prospective randomised control trials if changing to a next 
generation TKI in the face of a failure to attain the 3 month milestone will improve the 
eventual clinical outcome. The ideal trial would have two arms where TKI therapy needs to 
be changed at 3 or 6 months to refute or accept the ideal time point to alter therapy.  
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Chapter IV. Self reported adherence measures predict poor responses 
and correlate well with each other 
IV.1 Introduction 
Adherence - Definition 
WHO in 2001 had defined adherence as "the extent to which the patient follows medical 
instructions"117. This definition limits the role of the patient to being passive without much 
involvement. A more practical definition of adherence incorporates the behaviour of the 
patient ‘’the extent to which a person's behaviour - taking medication, corresponds with 
agreed recommendations from a health care provider’’118, 119. This not only adds weightage 
to the role a patient has in complying with the medical recommendations but also reiterates 
the fact that it is voluntary and depends on the patient’s willingness to comply with advice.  
Initially the problems related to non adherence was thought to be confined only to the 
chronic medical conditions like diabetes and hypertension.  One of the best examples of a 
change in mentality about adherence involved HIV. Adherence was considered very critical 
in HIV as it involved taking 3-4 drugs in a perfect sequence to avoid resistance. Poor 
adherence rates leading to less than ideal outcomes in HIV patients were an eye opener for 
clinicians. This was validated in a number of studies looking at adherence in HIV patients13, 
105, 120-122
.  
It was not plausible at the beginning to think that people taking oral anti-cancer medications 
could also be non-adherent to therapy. Emerging evidence over the years have shown 
adherence to oral medications to vary from 20 to 100%102. Adherence studies with TKI 
therapies have shown startling results as well. Noens et al showed that only 14% of all 
patients took the medications exactly as prescribed and only two thirds of the patients took 
 Page 62 of 171 
90% of their medications 94. Efficacie et al showed that only 53% of patients were adherent 
to TKI therapy in their observational study using questionnaires95. Marin et al has showed 
that only 60% of patients took their medications all the time as prescribed and 26% of 
patients were found to taking only 90% of the medications from a study done using MEMS 
(micro electronic monitoring system). Ganesan et al showed non adherence rates of 30% in 
an observational study of over 500 patients with CP CML on TKI therapy123. 
Adherence has been shown to be critical in achieving deeper molecular responses93. Marin 
et al showed that the 6 year probability of MMR was 94.5% with an adherence of >90% as 
compared to 28.4% probability with an adherence of <90% (p<0.001). Similarly the 6 year 
probability of complete molecular remission was 43.8% with an adherence of >90% as 
compared to 0% with a lower adherence (p=0.002). Ibrahim et al showed that poor 
adherence contributed to the loss of CCyR and imatinib failure in CP CML patients on 
imatinib therapy. The cumulative incidence of loss of CCyR was 26.8% with an adherence 
<85% as compared to 1.5% with an adherence of >85%. Given the significance of 
adherence to improved clinical outcomes, it became extremely important to find ways to 
monitor them. 
Adherence can be monitored by a number of methods93, 96, 97. The best would be continuous 
and directly observed monitoring, similar to DOPS (directly observed pill swallowing) used in 
multi drug resistant tuberculosis in some highly endemic countries. This method requires a 
lot of resources both financially and man power wise and hence unlikely to be a solution for 
rapid and effective monitoring tool in out-patient clinics. The next best solution is MEMS, 
which records the opening and closing of containers with the help of a micro chip embedded 
in the cap of the pill containers. We have shown that MEMS is superior to conventional 
methods in detecting non-adherence as the conventional methods sometimes tend to often 
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underestimate non-adherence93. The downside of MEMS is the financial constraints involved 
and is not practically feasible in most instances. Pill counting involves counting pills at the 
end of each visit to determine the number of pills left over to assess the medications that 
has been taken in the intervening period of time. Unfortunately pill counting does not reflect 
the period of adherence over time as patients may have taken additional pills leading up to 
the clinic visit as has been shown in the MEMS study by Marin et al which compared MEMS 
with self reporting and pill counting. Monitoring of blood levels can capture a measure of 
adherence leading to the clinic visit, but the downside is that it does not reflect adherence 
over a period of time (similar to HbA1c). Pharmacy and insurance databases have been the 
basis for a number of adherence studies, but they too have their downsides in that they do 
not reflect actual pill taking by patients, rather only the fact that the patients come for a refill 
on time or not. The last but not the least method of adherence monitoring involves self 
reported measures. Self reported measures have historically been used in a number of 
chronic conditions like diabetes, hypertension and HIV. More and more studies are being 
done using self reported measures of adherence in oral anti cancer therapy. The advantage 
of self reported measures is that they are simple, easy to use and do not involve financial 
burden97. The turnover can be rapid and they can be repeated used for monitoring 
adherence particularly useful in an out-patient setting. The downside of the self reported 
measures is that they often tend to under estimate non adherence as shown by Marin et al. 
The conditions under which the self report measures are recorded are also important as 
patients may feel they may be judged on the basis of their responses and hence likely to 
overestimate their level of adherence in the fear of not wanting to jeopardise the relationship 
with their healthcare professional.  
We used four self-reported adherence measures (described in the methods section below) 
to predict clinical responses. The visual adherence scale (VAS), Haynes et al question, Lu’s 
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adherence scale and diagnostic adherence to medicines scale (DAMS). The VAS has 
previously been shown to be useful in not only chronic conditions like diabetes, hypertension 
and HIV, but also TKI therapy94, 97, 101, 120. Haynes et al is recommended for predicting 
adherence to oral therapies using a simple question103. DAMS scale was designed to try and 
extract information pertaining to the rates and type of non-adherence (intentional and non-
intentional). It has been shown to be useful in identifying non adherence 106. Lu’s adherence 
scale was developed to detect non adherence in chronic conditions requiring oral 
therapies105. Using a questionnaire based study we tried to correlate adherence with clinical 
outcomes and also wished to see if the adherence measures correlated with one another.  
IV.2 Methods 
Patients: 
Two hundred and ninety six patients with CML in 1st chronic phase (CP) were recruited 
during out-patient appointments from six hospitals (Hammersmith Hospital, Nottingham 
University Hospital, Royal Liverpool Hospital, Gartnavel General Hospital, Monklands and 
Hairmyers Hospitals) across the UK between September 2011 and January 2013. They 
were all asked to complete the questionnaires. The patient characteristics are presented in 
table 3. One hundred and fifty two patients (51.4%) were on first line therapy, of whom 110 
were on imatinib, 22 were on nilotinib and 20 on dasatinib. Of the remaining 144 patients 
(48.6%) who had switched over to a second line therapy and beyond, 8 were on imatinib, 82 
on nilotinib, 40 patients on dasatinib, 8 on bosutinib and 6 were on ponatinib. The median 
age was 58 years (range 18 to 92 years) and the median duration on tki therapy was 37 
months (range from 3 to 156 months) 
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Adherence measures 
VAS 14 used a single item to determine a numerical value of adherence based on a visually 
coded scale. Patients were asked to mark what they thought was their average adherence 
to TKI during the last 7 days on a 12 cm scale. Each cm corresponds to an adherence of 
10% (0 to 120%). We used a 12cm scale instead of the typical 10cm scale to be able to 
capture over-adherence. 
Haynes et al103 was a single item asking patients to report the number of tablets/capsules 
they have missed in the last 7 days. DAMS106 was derived from the  Haynes et al question. 
DAMS measured adherence as a percentage of the medications taken over 7 days 
(Calculated by subtracting the missed doses from the total prescribed dose and expressing 
the result as a percentage). The scale also comprised of 3 other items from which it was 
possible to calculate rates of intentional and non intentional adherence in the last 7 days (we 
have not used the three other items in this study) 
Lu’s adherence scale105 included three questions. (The first two questions were likert scales 
asking patients the frequency with which they took their CML medications in the last 7 days 
and their ability to take all CML medicines as prescribed in the last 7 days). The responses 
to the two questions ranged from 0% to 100% at intervals of 20%. In the original Lu scale, 
the third question asked patients the % of time they have been adherent by oral questioning.  
As previous research 11 has shown respondents find it difficult to estimate percentages using 
the original Lu question, we used the VAS scale where patients estimated their measure of 
adherence on a visual scale. The three questions provided 3 answers and the average of 
the three was taken as the measure of adherence.   
Clinical responses 
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We compared the four adherence measures with responses based on the current European 
leukaemia network (ELN-2009) guidelines30. The patients were classified as having optimal, 
suboptimal and poor responses based on BCR-ABL PCR values and dates of measurement 
of responses. For the purposes of this study optimal and suboptimal responses were pooled 
together. The analysis was done to see if low adherence could predict poor responders. 
Statistical methods 
The relationship between adherence as a continuous variable and responses (optimal and 
poor responses) were explored by Logistic regression. Adherences were categorised into 
cut offs of <95%, <90%, <85% and <80% and compared with responses using the Fisher's 
exact test and chi square tests. Spearman’s correlation index was used to correlate the four 
adherence scales. Logistic regression was used to predict the best adherence cut off in a 
multivariate model. P vaues were 2 sided and 95% confidence intervals were used. Data 
was analysed using SPSS V.20. 
 
IV.3 Results 
 
IV.3.1 Visual adherence scale predicts for poor responses  
The median visual adherence scores for the 296 patients was 100% (range 50-120%). 
11.5% of patients had an adherence of <95% and 6.4 % of patients had an adherence of 
<90%.  The adherence scores from VAS predicted poor responses (Relative risk- 1.03, 
p=0.003). We have previously shown that adherence <90% correlates with poor clinical 
outcomes93. Nineteen patients with adherence <90% had significantly higher probability of 
having a poor response than the 274 patients with adherence levels >90% (36.8% vs. 15%, 
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p= 0.022). We tried to investigate the predictive value of other adherence cut offs (table 2) 
and thirty four patients with an adherence of <95% had a higher proportion of poor 
responders as compared to 259 patients with an adherence of >95% (29.4% vs. 14.7%, 
p=0.029). Similarly 18 patients with an adherence of <85% had a higher proportion of poor 
responders compared to 275 patients with an adherence of >85% (38.9% vs. 14.9%, p= 
0.015).  Eleven patients with an adherence of <80% had a higher proportion of poor 
responders as compared to 282 patients with an adherence of >80% (54.5% vs. 14.9%, 
p=0.003). 
Using a multivariate model, we tried to predict the best adherence cut off for predicting poor 
responders using the VAS. The adherence cut off of 80% (p=0.003) was found to have the 
best predictive value.  
 
IV.3.2 Haynes et al question correlated with poor responses and increasing missed 
doses correlated with poorer levels of responses 
Haynes et al question measured the number of tablets or capsules missed in the last 7 days. 
The median missed doses amongst the 296 patients was 0 (range 0-8). The missed doses 
estimated by Haynes et al was predictive of poor responses (OR 1.45, p<0.0001). Twenty 
two people who missed atleast 1 tablet (Haynes >1) in the last seven days had higher 
proportion of poor responses as compared to 271 people with no missed doses (36.4% vs. 
14.8%, p=0.015). Although Haynes et al was developed to reflect predictive value of atleast 
1 missed dose, we found increasing numbers of missed doses was predictive of poorer 
responses (table 2). Eleven patients who missed atleast 2 doses had a higher proportion of 
poor responders when compared to 282 patients with less than 2 missed doses (63.6% vs. 
14.5%, p<0.001). Ten people who had missed more than 3 doses had a higher proportion of 
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poor responders as compared to 283 people who had missed fewer than 3 doses (70% vs. 
14.5%, p<0.0001). Similarly 8 people with more than 4 missed doses had increased 
proportion of poor responders compared to people with fewer missed doses (75% vs. 
14.7%, p<0.0001). 
We tried to analyse different cut offs (different numbers of missed doses) that had the best 
predictive value in identifying poor responders. When analysed in a multivariate model, the 
most significant cut off was Haynes et al >3 (p<0.0001) in predicting poor responders. 
IV.3.3 Lu’s adherence scale was predictive of poor responses  
The median adherence by Lu’s measurement was 100% (range 33% to 107%). The 
adherence score from the scale was predictive of poor responders (Relative Risk- 1.03, 
p=0.021). Sixty nine patients with an adherence of <95% had a higher proportion of poor 
responders compared to 217 patients with an adherence of >95% (23.2% vs. 12.9%, p= 
0.039). Forty nine patients with an adherence <90% had higher proportion of poor 
responders as compared to 237 patients with an adherence >90% (26.5% vs. 13.1%, 
p=0.018). Similarly, patients with adherence cut offs of 85% and 80% had higher proportions 
of poor responders but did not reach statistical significance (table2).  
All adherence cut offs were analysed in a multivariate model and the cut off <90% (p=0.018) 
was the best predictor of poor responses.  
IV.3.4 Diagnostic adherence to medicines scale predicts poor responders 
 
The median adherence reported on the DAMS was 100% (range 50 to 100%) and 
adherence scores predicted poor responses (Relative Risk- 1.06, p=0.005). Thirty eight 
patients with an adherence of <95% had a higher proportion of poor responders compared 
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to 255 patients with an adherence of >95% (28.5% vs. 14.9%, p= 0.025). Twenty eight 
patients with an adherence <90% had a higher proportion of poor responders compared to 
265 patients with an adherence of >90% (39.3% vs. 14%, p= 0.002). Fourteen patients with 
an adherence of <85% had a higher proportion of poor responders compared to 279 patients 
with an adherence of >85% (57.1% vs. 14.3%, p<0.001). Similarly 13 patients with an 
adherence <80% had a higher proportion of poor responders compared to 280 patients with 
an adherence of >80% (53.8% vs. 14.6%, p=0.002). 
Using a multivariate model, the best independent predictor of poor response was cut 
off<85% (p<0.001).  
Haynes et al Qn predicts for the best responses and Self-reported adherence 
measures correlate with each other 
The four adherence scales were introduced into a multivariate model to see which one 
predicted the best for poor clinical responses. Haynes et al was found to be the best 
predictor of poor responses (OR- 1.5, p<0.0001). When we tried to combine the other 
adherence scales with Haynes et al, it did not improve the predictive ability of the scale.  
Haynes et al correlated well with VAS (Pearson’s -0.85, p<0.0001), adapted Lu’s scale 
(Pearson’s -0.662, p<0.0001) and DAMS (Pearson’s -0.943, p<0.0001). Similarly DAMS 
correlated with adapted Lu (Pearson’s 0.65, p<0.0001) and VAS (Pearson’s, p<0.0001). 
There appears to be a positive correlation between some and a negative correlation 
between others. Haynes shares a negative correlation with the other scales because of the 
fact that lower numbers (less missed doses) by Haynes scale correlates with higher 
numbers of the other scales (adherence). The other scales VAS, Lu’s and DAMS all share a 
positive correlation between them (Table 1 below). 
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Table 2- Bivariate correlations between the 4 adherence measures 
Adherence  Correlation  VAS  Haynes et al  Lu’s  DAMS  
VAS  
Pearson  1  -0.804  0.735  0.814  
Haynes et al  
Pearson  -0.804  1  -0.662  -0.943  
Lu’s  
Pearson  0.735  -0.662  1  0.656  
DAMS  
Pearson  0.814  -0.943  0.656  1  
VAS- visual adherence scale, DAMS- diagnostic adherence to medicines scale, correlations > 0.7 are considered 
good, p <0.0001 for all correlations. 
 
IV.4 Discussion: 
 
We have showed that the four self reported adherence measures (VAS, Haynes et al, Lu’s 
and DAMS) correlate with poor responders as defined by ELN guidelines. In the case of 
VAS, adherence cut offs of 95%, 90%, 85% and 80% proved to have predictive value in 
identifying poor responses. However the best cut off on a multivariate model was the cut off 
of 80%. In the case of Lu’s adherence scale, only cut offs of 95% and 90% were found to be 
significant. DAMS however could predict poor responders with all four cut offs (95%, 90%, 
85% and 80%). The best predictor on Lu’s and DAMS scales were 90% and 85% 
respectively. We have previously shown both these cut offs (90% adherence cut off 
identifying patients with increased 6 year probability of MMR93 and 85% cut off in predicting 
loss of CCyR124) to be significant in predicting clinical outcomes in our MEMS study. Haynes 
et al looked at adherence as a measure of the number of missed doses in a 7 day period 
and increasing numbers of missed doses was found to be highly predictive of poor 
responses and the best predictor on a multivariate model was more than 3 missed doses. 
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There appeared to be a correlation between the four adherence measures. The best 
correlations were seen between the Haynes et al and the DAMS scale. This should be 
interpreted in the fact that DAMS is a modification of the Haynes et al scale and hence the 
strength of the correlation. There appears to be a slightly weaker correlation between the 
Lu’s scale and the rest, indicating that the group identified as being non adherent by Lu’s 
appears different to those identified by the other scales, further strengthening the 
independent predictive value of the four scales. With some weak correlations, the 
significance of all of them appears to be extremely good due to the large number of patients 
in the analysis. 
The four self reported measures appeared to all identify a slightly different section of non 
adherent patients. We tried to predict the best out of the four  
and analysed them in a multivariate model, Haynes et al scale (predicting missed doses) 
was found to be the best predictor of poor responses. The other scales could not add 
sufficient value when they were combined with Haynes scale. 
We have shown that self report measures have good predictive value in identifying poor 
responses and also correlate with each other. They appear to have varying best cut offs, but 
the underlying fact that they all are able to predict clinically useful non-adherence is 
important. One possible explanation for the different cut offs could be because of different 
adherence patterns being picked up by the four scales. For example, Lu’s is a product of 3 
three questions, two of them not asking patients directly to indicate a numerical measure of 
adherence hence it may pick up more non-adherent patients (hence a higher cut off of 90%) 
as compared to VAS or DAMS which involve a more direct questioning and hence patients 
less likely to be forthcoming (deeper cut offs of 80% with VAS and 85% with DAMS).  We 
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propose these self-report measures are easy to use and can be used repeatedly to identify a 
pattern of non-adherence which would help in addressing issues related to non-adherence 
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Table 3: Patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(TKI- tyrosine kinase inhibitor) 
 
 
 
Criteria Frequency 
Current TKI therapy Imatinib-118 (40%) 
Nilotinib-104 (35%) 
Dasatinib-60 (20%) 
Bosutinib-8   (2.7%) 
Ponatinib-6   (2%) 
 
Age Median- 58 years 
(range 18 to 92 years) 
 
Duration of treatment Median- 37 months 
(range 3 to 156 months) 
Medication frequency Once a day- 202 (68%) 
Twice a day- 94 (32%) 
 
Current Treatment  First line TKI -              152 (51.4%) 
Second line TKI -          74 (25 %) 
Third line and beyond-   70 (23.6 %) 
 
Current TKI doses Imatinib (n=118) 
 400mg (72.8%) 
 300mg (11%) 
 600mg (7.6%) 
 800mg (3.3%) 
 Other doses (5.3%) 
 
Nilotinib (n=104) 
 800mg (35.5%) 
 600mg (26.9%) 
 400mg (28.8%) 
 200mg (5.7%) 
 Other doses (3.1%) 
Dasatinib (n=60) 
100mg (61.6%) 
 80mg (8.3%) 
 70mg (11.6%) 
 50mg (6.6%) 
 Other doses (11.9%) 
Bosutinib (n=8) 
500mg (25%) 
400mg (25%) 
300mg (25%) 
Other doses (25%) 
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Table 4- Probability of poor clinical responses related to adherence cut offs 
VAS- visual adherence scale, DAMS- diagnostic adherence scale, p values are 2 sided. Various 
non adherence cut offs were explored to identify poor responders.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scales Adherence cut offs Number Poor responses (%)  P value 
VAS 
 
 
<95%   yes- 34 
No-  259 
 
29.4% vs. 14.7% p= 0.029 
 
<90%    yes- 19 
No-  274 
 
36.8% vs. 15% p= 0.022 
 
<85%   yes- 18 
No-  275 
 
38.9% vs. 14.9% p= 0.016 
 
<80%   yes- 11 
No-  282 
 
54.5% vs. 14.9% p= 0.003  
Haynes et 
al 
≥1 missed dose   
 
yes- 22 
No-  271 
 
36.4% vs. 14.8% p= 0.015 
 
 
≥2 missed dose   yes- 11 
No-  282 
 
63.6% vs. 14.5% p <0.001 
 
≥3 missed dose   yes- 10 
No-  283 
 
70% vs. 14.5% p <0.0001 
≥4 missed dose   yes- 8 
No-  285 
 
75% vs. 14.7% p <0.0001 
Lu’s 
adherence 
scale 
<95%   yes- 69 
No-  217 
 
23.2% vs. 12.9% p= 0.039 
 
 
<90%   yes- 49 
No-  237 
 
26.5% vs. 13.1% p= 0.021 
<85%   yes- 37 
No-  249 
 
24.3% vs. 14.1% p= 0.106 
<80%   yes- 29 
No-  257 
 
24.1% vs. 14.4% p= 0.177 
DAMS <95%   yes- 38 
No-  255 
 
28.5% vs. 14.9% p= 0.025 
 
 
<90%   yes- 28 
No-  265 
 
39.3% vs. 14% P=0.002 
<85%   yes- 14 
No-  279 
 
57.1% vs. 14.3%  p<0.001 
<80%   yes- 13 
No-  280 
53.8% vs. 14.6% p=0.002 
 
 
 Page 75 of 171 
Chapter V. Relationship between self reported adherence and patient 
related factors  
 
V.1 Introduction 
WHO estimates that nearly half the patients in the developed countries fail to take their long 
term medications regularly 125. Adherence to TKI therapies has been identified to be a key 
determinant of improved outcomes amongst CML patients93, 94, 96, 124. The potential problems 
that can arise in patients on long term medications could arise either at initiation or 
compliance or early discontinuation126. A number of factors are thought to influence 
adherence to taking long term TKI therapy99. The factors could be patient related (intentional 
or non intentional non adherence) or physician related (patient education or adequate 
management of side effects).  Poor adherence to prescribed treatments are usually thought 
to be due to a combination of various factors like side effects, access to medications, patient 
education, routines and patient behaviours104. It has been postulated that a therapy that 
requires a higher degree of change in one’s routine or behaviour decreases compliance104, 
121
.  We have tried to study the influence of such patient related factors in a cohort of 296 
patients with CML in CP to see if they influence adherence to TKI therapy using a 
questionnaire based study.  
V.2 Methods 
5.2.1  Patients 
Two hundred and ninety six patients with chronic myeloid leukaemia in 1st chronic phase 
from 6 hospitals across the UK completed questionnaires on adherence measures and 
patient related factors. The patient cohort is the same one that has been used in the 
analysis for chapter 4 and their characteristics have been described in detail in the previous 
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chapter (chapter 4, tabular column 3). Briefly, the median age of the patients is 58 years 
(range 18 to 92 years). The median duration of TKI therapy was 37 months (range 3 to 156 
months).  
5.2.2  Questionnaire: 
We have used the questionnaire described in detail in the methods chapter (also included in 
the supplement section). From the questionnaire we have used questions (outlined in tables 
5-8) pertaining to daily routine (n=5), communication (n=7), internet support (n=5) and taking 
the medications (n=13) (sections 5, 6, 7 and 8 respectively). There were a total of 30 
questions that we have used in this analysis. All the questions had 5 possible answers 
marked from 1 to 5 (1- strongly agree, 2- agree, 3-unsure, 4- disagree, 5- strongly disagree). 
The positively worded questions were marked from 1 to 5 and the negatively worded 
questions were marked from 5 to 1 for the purposes of this analysis.  
In order to study the relationship between adherence and patient related factors we have 
done 2 types of analysis. In the first we have analysed the questions individually (n=30) to 
see if they predicted for adherence. Second, as a group (i.e. like Daily routine (5 questions) 
was analysed as one to see if they predicted for adherence. The sections were considered 
to be a single blocks. The blocks were meant to convey the mood or sense of the 5 
questions it includes, for example the first block includes 5 questions on daily routine and 
the block referrers to routines remaining the same in spite of the cml treatment. An 
agreement in the form of answers 1 or 2 would mean that patients feel their routines have 
not changed. We tried to see if the answers in agreement to the questions predicted high or 
low adherence.  
5.2.3  Statistical methods: 
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Briefly, the questionnaire consists of 8 sections in which we have used sections 5, 6, 7 and 8 
for the purposes of this analysis. The questions (outlined in table 5,6,7 & 8) were considered 
both independently and as a block (each section) to see if they predicted for adherence. The 
block refers to the mean of the questions in each section, for example the first section on 
daily routines has 5 questions. The questions were coded to ensure they reflected the fact 
that the routines had not changed despite cml treatment. We then tried to see if this 
predicted for adherence categories.  
The average of the answers for each block was used in the analysis when being considered 
together. The answers ranged from 1 to 5 and these were used as a continuous variable for 
the purposes of analysis. The four adherence measures (Visual adherence scale, Haynes et 
al question, Lu’s and DAMS) have been described in detail in the previous chapter. The four 
adherence measures were categorised into 4 categories (table 9) and these were used as a 
categorical variable. We tried to predict adherence (dependent variable) using the answers 
from the questions (independent variable) using ordinal logistic regression. P values were 2 
sided and were corrected accordingly.  
V.3 Results: 
V.3.1 Section 5: Daily routines: description of answers 
Daily routines of patients do not seem to be affected by their CML treatment. Majority of 
patients (70%) felt that their routines remained the same and even when it changed, they 
(80%) were able to adapt easily to it. The questions involving daily routine and the median 
value of the answers are given in the table below (table 5). 
Eighty two percent of patients felt their mealtimes had not changed much since they started 
taking their TKI therapy. An interesting point to note is that majority of the patients did not 
have support at home; with 79% saying they did not have someone helping them with 
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managing their treatment at home. Most of the patients (65%) did not travel long to get to 
their hospital for treatment.  
Table 5- Daily routine questions & Answers 
The answers were codified as classified as 1: strongly agree, 2: agree, 3: unsure, 4: disagree and 5: strongly disagree. The 
first column reflects the percentage of patients who agree or strongly agree with the question. The second column reflects 
the percentage of patients who disagree or strongly disagree with the question and the third column represents the median 
of the answers to the question.   
Questions (Agree/strongly 
agree) % 
(Disagree/strongly 
disagree) % median 
1. My mealtimes have NOT changed much since I started taking 
my current medicine 
82% 15.2% 2 
2. Someone helps me with managing my treatment at home 18% 77.4% 4 
3. My daily routine changed a lot when I started my current CML 
medicine 
27.8% 65% 4 
4. I found it easy to adapt to the routine of taking my current 
medicine 
80.4% 12.4% 2 
5. I travel for a long time to get to my CML appointments at the 
hospital 
33.3% 60% 4 
(Questions 3 and 5 are worded negatively, hence a median value in excess of three for these mean a disagreement to 
the questions, which would in fact mean agreeing with a positively worded question) 
 
V.3.2 Section 6: Communication with the physician: description of answers 
The section of the study deals with communication between the patient and the treating 
physician. The median and the percentage of the answers to the communication questions 
are tabulated below (table 6). 
The questions were intended to see if there was good communication between physicians’ 
and the patients and if that influenced adherence. Ninety two percent of patients were told 
how to take their medicines as per advice and 78% of patients agreed that their doctor had 
spoken to them about how to manage side effects from their treatment.  
The patients agreed with statements where they were asked if their physician had advised 
them appropriately about their medicines, cml management and dealing with side effects. 
Eighty percent of patients concurred their doctor has asked them about how they are getting 
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on with taking their medicine. Eighty seven percent of them felt their doctor has explained 
how to manage their cml treatment. Ninety two percent agreed that their doctor has advised 
them to take their medicine as prescribed.  
Patients seemed to understand what their physicians told them (89%) and even when they 
did not, majority (90%) asked for clarifications and explanations. Ninety five percent of 
patients think their doctor listens to what they have to say.  
Table 6- Communication questions & answers 
The answers were codified as classified as 1: strongly agree, 2: agree, 3: unsure, 4: disagree and 5: strongly disagree. The 
first columns reflect the percentage of patients who agree or strongly agree with the question. The second column reflects 
the percentage of patients who disagree or strongly disagree with the question and the third column represents the median 
of the answers to the question.   
Questions (Agree/strongly 
agree) % 
(Disagree/strongly 
disagree) % 
Median 
6. My doctor has spoken to me about how to manage side effects 
from my current CML medicine 
78% 13% 2 
7. My doctor does NOT generally ask me about how I am getting 
on with taking my medicine 
17.2% 80.4% 4 
8. My doctor has explained to me how to manage my current CML 
treatment 
87.6% 8.6% 2 
9. My doctor has told me to take my medicine exactly as prescribed 92% 4% 1 
10. I generally do NOT understand what my doctor says about my 
CML treatment 
6.2% 89% 5 
11. If I do NOT understand what my doctor says I generally ask the 
doctor to explain 
87.3% 11.6% 2 
12. My doctor does NOT listen to what I have to say 3.1% 95% 5 
(Questions 7, 10 and 12 are worded negatively; hence a median value in excess of three means a disagreement to the 
questions, which would in fact mean agreeing with a positively worded question) 
 
 
V.3.3 Section 7: Internet usage and patient support groups 
In our study, we included this section to understand how much the patients used internet to 
learn about their CML treatment and to see if they utilised the services of the support 
groups. The median values of the answers given by the patients to the questions pertaining 
to internet are provided in the table below (table 7). 
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The overwhelming message seems to be that the patients did not use the internet much nor 
did they utilise the support service networks, in fact nearly 52% of patients do not search the 
internet to find out information about their CML.  
Seventy three percent do not use the CML internet forums or networks. Eighty three percent 
are not in contact with CML patient advocacy groups. Eighty six percent of patients who 
answered the questionnaire have not used the CML patient support services in the form of a 
councillor or a psychologist and an equal number have never been in contact with a support 
person who is also a CML patient.  
Table 7- Internet support questions & answers 
The answers were codified as classified as 1: strongly agree, 2: agree, 3: unsure, 4: disagree and 5: strongly disagree. The 
first columns reflect the percentage of patients who agree or strongly agree with the question. The second column reflects 
the percentage of patients who disagree or strongly disagree with the question and the third column represents the median 
of the answers to the question.   
Questions (Agree/strongly 
agree) % 
(Disagree/strongly 
disagree) % Median 
16. I search the internet to find information about my 
CML 
43.3% 52.2% 3 
17.  I use online CML internet forums / networks 18.5% 76% 4 
18.  I am in contact with CML patient advocacy groups 8.8% 86% 4 
19. I have used CML patient support services  (e.g. 
councillor / psychologist) 
7.4% 89.5% 4 
20. I have been in contact with support person who is 
also a CML patient 
8.8% 87.4% 4 
        (Values higher than 3 indicate a strong disagreement with the question) 
V.3.4 Section 8: Taking the medications: description of the answers 
Thirteen questions (detailed in table 8 below) on taking the medications represented 
patients’ views on problems faced when having to take their medications. Over 90% of 
patients did not have problems whilst physically taking the medications in terms of 
swallowing, packaging or having reminders to help them. In fact nearly three fourths of the 
patients do not keep their medicines in little compartments with timings and days of the 
week and also not use an alarm to help them take their CML medications.  
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In our study, we identified that generally patients are not forgetful in taking their medications 
and appear to have strong perceptions when it comes to it. When asked about missing 
doses, 78% of the patients interviewed do not forget to take their CML medicine. Ninety 
percent of patients do not stop taking their medications for some reason without consulting 
their doctor. Thirty two percent of patients were told by their doctors that it did not matter if 
they missed an occasional dose.  
We tried to find out about patients’ perceptions on the effect of missed doses with their 
clinical outcomes. Only 64% disagreed with the fact that their response will not be affected if 
they miss an occasional dose of their CML medicine. When asked if the patients did miss an 
occasional dose, 25% said yes. On direct questioning, 90% felt they would not skip their 
CML medicine and two thirds of patients (60%) agreed that they would be worried if they 
missed a dose.  
To understand the physicians role in patients perceptions, 30% of patients felt that they have 
been told that they needed to take every single dose of their cml medications or they might 
not work. The median vaues of the answers to the questions in this section are outlined 
below (table 8). 
Table 8- Taking the medicines questions & answers 
The answers were codified as classified as 1: strongly agree, 2: agree, 3: unsure, 4: disagree and 5: strongly disagree. The 
first columns reflect the percentage of patients who agree or strongly agree with the question. The second column reflects 
the percentage of patients who disagree or strongly disagree with the question and the third column represents the median 
of the answers to the question.   
Questions (Agree/strongly 
agree) % 
(Disagree/strongly 
disagree) % 
Median 
21.  I find it difficult to swallow my CML medicine 5.5.% 93.2% 5 
22.  I sometimes forget to take my medicine 19.3% 88% 4 
23.  The doctors have said that it does NOT matter if I miss the occasional 
dose 
18.7% 68.4% 4 
24.  I find it difficult to take the medicine out of the packaging 6.4% 92.2% 5 
25.   Sometimes I stop taking my CML medicine for   some reason for a 
few days without consulting my doctor 
6.8% 92.2% 5 
26.  It will NOT affect my response if I miss the occasional dose of 17% 65% 4 
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medicine 
27. I keep my medicine in a box with little compartments for timings and 
days of the week 
22.8% 75% 4 
28. I was off my medicine for some time and it did NOT affect my CML 
much 
26.3% 61.7% 2 
29. I think it is ok to miss a few doses now and again 13.4% 79.4% 5 
30. I sometimes decide to skip doses of my current CML medicine 6.5% 91.4% 5 
31. I use an alarm to help me remember to take my CML medicine 19.7% 88.3% 4 
32. I would feel worried if I missed a dose 61.6% 28.4% 2 
33. I have been told that I need to take every single dose or my treatment 
might NOT work 
30.3% 46.9% 3 
 
V.3.5 Adherence measures  
The four adherence measures (VAS, Lu’s adherence, DAMS and Haynes et al) were 
calculated as described in detail in the methods chapter and chapter 4.  
Visual adherence scale (VAS) was based a single question and the self reported adherence 
ranged from 50% to 120% with a median of 100%. 49 patients (16.5%) had a self reported 
adherence of less than 100%. VAS was divided into 4 categories (<80%, 81-90%, 91-98% 
and >98%) to facilitate this analysis. Similarly self reported Lu’s adherence had a median 
value of 100% (range 33% to 107%). DAMS adherence values had a median of 100% 
(range 50 to 100%). Both Lu’s and DAMS were categorised into the same 4 categories as 
VAS. Haynes et al question measured the number of missed doses through a single 
question. It was also divided into 4 categories based on the number of missed doses (no 
missed doses, 1 missed dose, 2 missed doses and greater than 3 missed doses) for the 
purposes of this analysis. The median missed dose was 0 and the range was 0 to 8. The 
adherence measures categorised to 4 categories (0 to 3) and the number of patients in each 
category has been summarised below (table 9) 
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Table 9- Adherence categories with patients according to the 4 adherence measures 
 
These 4 categories of adherence measures were used as a categorical variable to compare 
against the answers to the questions both individually and as a group of questions in each 
category.  
V.3.6 Predictive value of patient related factors on self reported measures of 
adherence. 
Block: (description) 
Briefly, as described in the methods, when the entire section was analysed as one, it is 
referred to as the block. The block is meant to convey the meaning of all the questions as 
one, for example in the section on daily routines, there are 5 questions. When being 
analysed as a block, it refers to ‘’the routines have not changed much since cml therapy was 
commenced’’. The median of all the 5 answers are used and the average is taken to be the 
number representative of the block and it can range from 1 (strongly agree) to 5 (strongly 
disagree). A value closer to 1 would mean the people agree with the statement that their 
routines have not changed and closer to 5 would mean they disagree. 
 
V.3.6.1 Daily routine (5 questions) 
The answers were first compared as a block and secondly analysed individually to see if 
they predicted for the 4 categories of adherence. The questions were re-coded to reflect the 
Categorical 
variables 
Adherence 
categories  
         Number of patients 
VAS  Lu’s  DAMS 
0 <80% 16 28 13 
1 80-90% 17 21 15 
2 91-98% 14 26 16 
3 >98% 239 203 241 
Categorical 
variables 
(missed doses) patients 
0 >=3 doses 11 
1 2 doses 11 
2 1 doses 24 
3 0 dose 250 
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fact that the routines have not changed or have been affected despite cml therapy. The 
median of these 5 questions reflected the mood of the block.  
 
V.3.6.1a Questions when analysed as a block: (No change in routines predicted 
for higher adherence) 
The median value of the block is 2 (agreement).  The block refers to the routines being 
unchanged by CML treatment. The daily routine questions and their answers did not predict 
for adherence by VAS (Odds Ratio (OR) -.21, p = 0.209). The daily routine block was 
predictive of the missed doses (Haynes et al) (OR +0.43, p=0.053).  Patients whose daily 
routines were unchanged since the commencement of cml therapy predicted for higher 
adherence using Lu’s scale (OR -1.05, p<0.0001). When the routines were unchanged, the 
answers were not predictive of the adherence measurements by DAMS (OR -.39, p=0.085). 
The high negative factor (OR) estimate implies that for every 0.2 reduction in the answer 
score, the adherence increases by 5%. The factor is positive for the Haynes scale; here it 
implies a positive correlation as a reduction of missed doses is considered significant. 
V.3.6.1b Questions when analysed individually using the 4 adherence measures: 
The questions (n=5) were individually analysed using logistic regression to see if they 
predicted for the adherence categories by the four measures. 
Using VAS 
Questions 2 (Someone helps me with managing my treatment at home); p=0.046 and 3 (My 
daily routine changed a lot when I started my current CML medicine); p=0.05 were 
independently predictive of adherence by VAS. The answers to the other 3 questions could 
not predict adherence using VAS.  
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Using Haynes et al: 
Question 2 (Someone helps me with managing my treatment at home); p=0.01 was 
independently predictive of the missed doses by Haynes et al. The answers to the other 4 
questions could not predict for adherence using Haynes scale. 
Using Lu’s adherence scale: 
Question 2 (Someone helps me with managing my treatment at home); p=0.019 was 
independently predictive of adherence by Lu’s. The answers to questions 3 (My daily routine 
changed a lot when I started my current CML medicine); p= 0.02 and 4 (I found it easy to 
adapt to the routine of taking my current medicine); p= 0.002 were found to have 
independent predictive values. The answers to the other 2 questions could not predict 
adherence using Lu’s.  
DAMS: 
Question 2 (Someone helps me with managing my treatment at home); p=0.03 was 
independently predictive of the DAMS. The answers to the other 4 questions could not 
predict adherence using DAMS adherence measures.  
V.3.6.2 Communication with the doctors (7 questions) 
V.3.6.2a Questions when analysed as a block (Good communication between 
patients and doctors predicted for adherence) 
The median value of the block was 2, refers to good communication between the patients 
and doctors. This did not predict for adherence by VAS (OR -.38, p=0.24) or by Haynes et al 
(OR +.3, p=0.132). The answers to the communication questions, referring to good 
communication between patients and doctors predicted for high adherence by Lu’s (OR -.5, 
 Page 86 of 171 
p=0.038) and not by the DAMS scale (OR -.31, p=0.108). The negative factor estimate (OR) 
in the case of Lu’s adherence implies that for every 0.2 reduction in the value of the answer, 
there is an increase in adherence by 2.5%.  
 
V.3.6.2b Questions when analysed individually to look for predictive value: 
The questions (n=7) were individually analysed using logistic regression to see if they 
predicted for the adherence categories by the four measures. 
The communication questions did not have any independent predictive in predicting 
adherence by any of the four scales.  
V.3.6.3 Internet and support services network usage: (5 questions) 
V.3.6.3a Questions when analysed as a block using the adherence measures 
(usage of internet and support services did not predict for higher adherence) 
The median value of the block was 4 implying poor patient’s usage of the internet and 
support services. The usage of internet and support services did not predict adherence by 
VAS (OR -.22, p=0.27). Patients usage of internet and the services of the support groups 
was not predictive adherence by Haynes et al (OR +.19, p=0.3) or Lu’s adherence 
categories (OR -.02, p=0.288). Similarly, the 5 answers as a block was not predictive of 
DAMS adherence categories either (OR -.17, p=0.289). There is a change in adherence by 
2.5% for 0.2 reduction in the value of OR.  
V.3.6.3b Questions when analysed individually to look for predictive value: 
The questions (n=5) were individually analysed using logistic regression to see if they 
predicted for the adherence categories by the four measures. 
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Using VAS: 
Answers to question 3 (I am in contact with CML patient advocacy groups) could 
independently predict for adherence (p=0.034). The other 4 questions and their answers 
could not predict for adherence.  
Haynes et al question: 
None of the 5 questions had any significant independent predictive value in predicting for 
adherence using Haynes et al. 
Lu’s adherence categories 
Answers to question 3 (I am in contact with CML patient advocacy groups) could 
independent predict for adherence using Lu’s (p=0.032). The other 4 questions and their 
answers could not predict for adherence.  
DAMS: 
None of the 5 questions had any significant independent predictive value in predicting for 
adherence using DAMS. 
 
V.3.6.4 Taking the medications (13 questions) 
V.3.6.4a Questions when analysed as a block using the adherence measures 
(Patients views on taking the medications, i.e. patients who had less problems taking 
their medications had higher adherence) 
The median value of the block is 2; implying patients are not having problems whilst taking 
their medications. This correlated with high adherence as measured by the four categories 
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of VAS (OR -1.31, p<0.001). Similarly, the block was highly predictive of high adherence by 
Haynes et al (OR +1.59, p<0.0001), i.e. patients who did not have problems missed fewer 
doses of their TKI.  The block was also highly predictive of higher categories of adherence 
by Lu’s (OR -1.23, p=0.001) and the DAMS categories (OR -1.45, p<0.0001). The high 
factor estimates (OR) establishes the significance of the block in predicting adherence. The 
negative values in the case of VAS, Lu’s and DAMS indicates an increase of >10% in 
adherence for every 0.2 reduction in the value of the answers. Similarly a positive estimate 
for Haynes correlates with a decrease in missed dose by 1.6 for every 0.2 reduction in the 
value of the answer. 
V.3.6.4b Questions when analysed individually to look for predictive value: 
The questions (n=13) were individually analysed using logistic regression to see if they 
predicted for the adherence categories by the four measures. 
VAS: 
There were three questions that had independent predictive value. Answers to question 26 
(It will NOT affect my response if I miss the occasional dose of medicine) was predictive of 
VAS; p=0.01. Similarly answers to question 30 (I sometimes decide to skip doses of my 
current CML medicine); p=0.022 and question 31(I use an alarm to help me remember to 
take my CML medicine); p=0.01 were predictive of adherence by VAS independently. The 
other 10 questions were not found to have independent predictive value.  
Haynes et al 
There were four questions that had independent predictive value. Question 22 (I sometimes 
forget to take my medicine) was found to be predictive of adherence by Haynes et al; 
p=0.05.  Answers to question 26 (It will NOT affect my response if I miss the occasional 
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dose of medicine) was predictive; p=0.003. Similarly answers to question 30 (I sometimes 
decide to skip doses of my current CML medicine); p=0.002 and question 31(I use an alarm 
to help me remember to take my CML medicine); p=0.02 were predictive of missed doses by 
Haynes et al independently. The other 9 questions were not found to have independent 
predictive value.  
 
Lu’s adherence categories 
There were four questions that had independent predictive value. Question 22 (I sometimes 
forget to take my medicine) was found to be predictive of adherence by Lu’s categories; 
p=0.04.  Answers to question 26 (It will NOT affect my response if I miss the occasional 
dose of medicine) was predictive; p=0.02. Similarly answers to question 30 (I sometimes 
decide to skip doses of my current CML medicine); p=0.05 and question 31(I use an alarm 
to help me remember to take my CML medicine); p=0.05 were predictive of adherence by 
Lu’s independently. The other 9 questions were not found to have independent predictive 
value.  
DAMS 
There were four questions that had independent predictive value. Question 22 (I sometimes 
forget to take my medicine) was found to be predictive of adherence by DAMS categories; 
p=0.022.  Answers to question 26 (It will NOT affect my response if I miss the occasional 
dose of medicine) was predictive; p=0.004. Similarly answers to question 30 (I sometimes 
decide to skip doses of my current CML medicine); p=0.005 and question 31(I use an alarm 
to help me remember to take my CML medicine); p=0.02 were predictive of adherence by 
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DAMS independently. The other 10 questions were not found to have independent 
predictive value.  
V.3.7 Questions that were found to have independent prognostic value in predicting 
adherence categories are combined together 
There were a total of 30 questions of which 8 were found to be significant in predicting poor 
adherences using the 4 scales. Of the 8, two questions (Question 22 and 30) were found to 
directly reflect adherence, hence they were excluded.  
Using the remaining six questions [Someone helps me with managing my treatment at home 
(Q2),  My daily routine changed a lot when I started my current CML medicine (Q3),  I found 
it easy to adapt to the routine of taking my current medicine(Q4),  I am in contact with CML 
patient advocacy groups (Q18),  It will NOT affect my response if I miss the occasional dose 
of medicine (Q26) and  I use an alarm to help me remember to take my CML 
medicine(Q31)], we tried to create a block of questions to test their ability to predict 
adherence both as a group and individually.  
On multivariate analysis, 4 questions were found to predict adherence independently. 
Question 2 (p=0.04), 3(p=0.005), 4(p=0.001) and 26(p=0.009). 
These 4 questions as a block were found to be highly significant in their ability to predict 
adherence (VAS, p=0.001; Haynes et al, p=0.001 and Lu’s, p<0.0001 and DAMS. P=0.001).  
V.4 Discussion 
In our study we identified that Patient related factors like daily routines, communication with 
physician and more importantly factors related to the patient experience in taking the 
medications were found to influence adherence as we had speculated.  
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Patients’ day to day routines, when they remain unaltered with their CML therapy was 
associated with higher adherence as measured by Lu’s adherence scale and was also 
predictive of lower number of missed TKI doses. However when the routines remain the 
same, they were not found to be significantly predictive of adherence by the other 2 
measures (VAS and DAMS). This could be explained by the higher numbers of people being 
found non adherent by the Lu’s method and hence shows a better relationship compared to 
other methods. Individual answers indicate that majority of the patients felt their routines had 
not changed following their CML therapy, but patients found it easy to adapt change in 
routine when it happened. Most of the patients surveyed did not have support at home to 
help them manage their CML treatment. It appears that when routines remain the same or 
when patients are able to adjust to the routines without a great deal of change to their 
lifestyle, it results in better adherences. It may be speculated that that people who are able 
to adjust their lifestyle are more likely to cope with issues arising out of their CML 
management and hence appear to be better at adhering to the therapy as prescribed.  
Good communication between the patient and their treating physician predicted for higher 
adherence categories by Lu’s adherence scale (p=0.038) and not by the other three 
adherence measures. One possible explanation for the predictive value using Lu’s and not 
the others could be because of the nature of the adherence estimation between the four 
measures. Lu’s adherence scale includes more patients as being not adherent (25% not 
having 100% adherence as compared to between 15 to 16.5% for the other 3) as compared 
to the other adherence measures, prompting a speculation that it captures more people with 
borderline non adherence than may have otherwise been estimated by the other three 
measures. Moreover Lu’s scale includes questions that detect non adherence through 
indirect means whereas the other three adherence measurements appear to involve direct 
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questioning. This may potentially have an effect in under reporting of adherence due to the 
fear of repercussion from the healthcare professionals by the patient.  
Individually, none of the questions addressing communication between patients and doctors 
could predict adherence on its own. Majority of the people were happy with the 
communication to and fro from their doctor and felt they received enough information 
pertaining to the CML medication and their management. The patients understood what their 
doctor said and majority did ask for an explanation when they did not understand. 
Patients admit to reduced usage of the internet with just over half of them admitting to find 
out information about their CML online. Usage of the internet and patient support groups 
was found to be not predictive of adherence by any of the 4 adherence measures. 
Interestingly the use of internet was not associated with age; 25% of the patients younger 
than 60 years use the internet as compared to 29% of patients older than 60 years (p=0.6). 
A significant majority of the patients (90%) also appeared to not use the services of the 
support networks both online and in person to help them deal with issues arising out of their 
CML management. Patients who use the services of the patient advocacy groups were 2 
times more likely to be adherent as compared to people who did not.  It is not very clear as 
to the possible reason behind this but could be speculated that association with the patient 
advocacy groups probably made the patients more aware of the current issues in CML and 
the importance of adherence in attaining better clinical outcomes.  
This could  potentially be an area to target as these support services could not only be very 
helpful for the patients to deal with issues arising out of management of their CML but also 
potentially educational messages can be sent across through such forums. On the other 
hand, the message from the study could mean efforts to promote more online educational 
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activities and information may not be useful in reaching the intended audience and other 
forms of information dissipation needs to be looked at.  
In our study, we found that the majority of patients are not troubled by issues related to 
taking medications like packaging, swallowing, forgetting to take and the use of reminders to 
help them take it regularly. The answers to this effect were highly predictive of adherence by 
all the 4 adherence measures (VAS, p<0.001; Haynes et al, p<0.0001; Lu’s, p=0.001; 
DAMS, p<0.0001). When patients were questioned as to what they thought of missing a 
dose occasionally or would they be worried if they missed one, the answers were indeed 
startling that only a third would actually be worried. Such views are likely to influence 
adherence significantly. 
Majority of the patients still seemed to follow the advice given in that they would not stop 
taking the medications without consulting their doctor. Only three out of 10 patients admitted 
that they had been told by their doctor to take every single medication or their treatment 
might not work. These two statements convey a very important message for the clinicians in 
that a proper advice regarding compliance to therapy would go a long way in influencing 
patient behaviour. Even if nothing else is discussed in the clinic, it seems just perhaps 
reminding the patients to take every tablet as prescribed could go a long way to improving 
adherence.  
We tried to combine the questions that had an independent prognostic value in predicting 
adherence. After excluding the 2 questions that seemed to directly reflect adherence, there 
were 4 questions which were found to be independent predictors in the multivariate analysis, 
namely someone helps me with managing my treatment at home (Q2), (RR=2.87, p=0.02),  
My daily routine changed a lot when I started my current CML medicine (Q3), (RR=4.54, 
p=0.005)  I found it easy to adapt to the routine of taking my current medicine (Q4), 
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(RR=5.23, p=0.001) and It will NOT affect my response if I miss the occasional dose of 
medicine (Q26) (RR- 4.3, p=0.009). As ours was a retrospective observational study, these 
questions and their relationship to adherence needs prospective validation in the setting of 
clinical trial. We propose that these potentially could be incorporated into clinical practice to 
obtain surrogate markers for adherence to TKI therapy and also could help gain an insight 
into patient related factors influencing adherence.  
Value of surrogate markers to deal with issues of anonymity 
The perceived downside to self reported adherence could be to do with anonymous 
responses and the way the results could be incorporated into practice without compromising 
the confidentiality. This day and age where time is of essence, a shorter questionnaire that 
does not involve direct questioning about non adherence could be of value in day to day 
clinical practice as a surrogate for self reported measures. Moreover it can help to build a 
pattern of adherence over a period of time which could help clinicians address issues related 
to compliance if they see a downward trend rather than a one off value.  
This short questionnaire could in fact be coupled with an adherence measure to both 
objectively determine adherence and also study factors that could be influencing adherence 
as surrogate markers.  
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Chapter VI. Relationship between self reported adherence and patient 
related factors II  
 
VI.1 Introduction: 
 
 
Oral anticancer therapies have revolutionised the way cancers are managed these days and 
the most classic example is the use of tyrosine kinase inhibitors to treat CP CML. Tyrosine 
kinase inhibitors have changed outlook of CML from being a fatal condition to more of a 
chronic condition127. The onus of treatment has definitely moved away from the treating 
physician or the healthcare professional towards the patient with the improvements in oral 
therapies. Such changes have brought into focus numerous factors that could potentially be 
influencing patient’s behaviours and state of mind thereby indirectly having an effect on 
adherence to therapy and subsequently clinical outcomes. 
We and others have previously shown that adherence to therapy is critical to achieving 
optimal outcomes in CP CML patients on TKI therapy91, 96, 124. Research on factors 
influencing adherence behaviour has gained increasing importance of late. This is to 
identify, understand and implement strategies to overcome the possible influence of the 
factors on adherence to oral therapies. In this study we try to understand the relationship 
between patient’s views about medicines and its effect on adherence and outcomes through 
a BMQ (Beliefs about medicines) questionnaire (explained in methods section)128. We have 
also tried to study the influence of anxiety and depression on adherence and clinical 
outcomes through a validated HADS (Hospital anxiety and depression) scale (methods 
section)109. Finally we tried to predict if quality of life [FACT-G (Functional Assessment of 
Cancer Therapy-General) scale, explained below)108 was dependent upon adherence or 
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outcomes and whether it was related to anxiety, depression or concerns patients had with 
regards to their medicines. Our study was a questionnaire based one involving 296 CP CML 
patients in outpatient clinics. 
 
 
VI.2 Methods 
 
Patients: 
 
Two hundred and ninety six patients with chronic myeloid leukaemia in 1st chronic phase 
from 6 hospitals across the UK completed questionnaires on adherence measures and 
patient related factors. The patient cohort is the same one that has been used in the 
analysis for chapter 4 and their characteristics have been described in detail in the previous 
chapter (chapter 4, tabular column 3). Briefly, the median age of the patients is 58 years 
(range 18 to 92 years). The median duration of TKI therapy was 37 months (range 3 to 156 
months).  
Questionnaires: 
There are a total of twelve sections in the questionnaire (described in detail in methods 
chapter and also included in supplement section) out of which we have used three sections 
of the questionnaire (BMQ, HADS scale and the FACT-G scale) in this study. Briefly, the 
BMQ (beliefs about medicines) questionnaire was to determine patient’s beliefs about 
medicines128, HADS (Hospital anxiety and depression scale) was a 14 question scale to 
identify anxiety and depression amongst hospital patients109 and FACT-G (Functional 
Assessment of Cancer Therapy-General) is a validated quality of life questionnaire108. The 
questions that make up these scales are included in the supplement section 1.  
 Page 97 of 171 
Beliefs about medicines (BMQ) questionnaire: 
The BMQ128 is a 10 item questionnaire assessing the cognitive representation of medication 
(Questions included as supplement y and described in the methods section). The BMQ 
comprises two sub-scales: Necessity scale assesses patients' beliefs about their personal 
need for the medicine and how important the medicine is in maintaining their health now and 
in the future. Concerns scale assesses perceptions of the potential negative consequences 
of taking the medicine including concerns related to beliefs about long-term effects, 
dependence and other disruptive effects. 
Each item of the BMQ scale is scored on a 5-point Likert-type scale ranging from 
1 = strongly agree, 2 = agree, 3 = uncertain, 4 = disagree and 5 = strongly disagree. 
Specific-Necessity and Specific-Concerns scales have 5 items and scores range from 5 to 
25.  
Scores obtained for the individual items within each scale are summed to give a scale score 
(necessity scale and concerns scale). Higher Necessity scores represent stronger 
perceptions of personal need for the medication to maintain health now and in the future. 
Higher Concerns scores represent stronger concerns about the potential negative effects of 
the medication.  
A necessity concerns differential is calculated by subtracting the necessity scores from 
concerns and the range obtained could vary from -20 to 20. A negative score represents 
preponderance of concerns over necessity and a positive score preponderance of necessity 
over concerns. The necessity and concerns scores are analysed as a continuous variable to 
see if they predict for adherence (also to see if they predicted for intentional or non 
intentional non adherence, as described in the results section), response, relationship to 
anxiety and depression. Similar analysis is repeated using the necessity concerns 
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differential. Here the necessity concerns differential is coded as 1 or 0 representing 
concerns and necessity respectively [score from -20 to 0 coded as ‘’1’’ (concerns) and 1 to 
20 coded as ‘’0’’ (necessity)]. This categorical variable is then used to predict for adherence, 
its type, clinical response and relationship to anxiety and depression.  
HADS scale (Hospital anxiety and depression scale) 
HADS109 is a well validated fourteen item scale of which 7 of the items relate to anxiety and 
seven relate to depression (Questions included as supplement z and described in the 
methods section). All the 14 questions have 4 possible answers, scored using a likert type 
scale. Each item on the questionnaire is scored from 0-3 and this means that a person can 
score between 0 and 21 for either anxiety or depression. A cut off point of 8 identifies 
anxiety or depression. The anxiety and depression scores are also categorised as 0 and 1. 
The anxiety and depression scores as both a continuous variable and categorical variable is 
then analysed to look for relationships with adherence and clinical outcomes.  
FACT-G (Functional Assessment of Cancer Therapy-General) : 
FACT-G108 comprises of 27 questions divided into four primary Quality of life domains: 
Physical Well-Being (PWB) (7 questions), Social/Family Well-Being (SWB) (7 questions), 
Emotional Well-Being (EWB) (6 questions), and Functional Well-Being (FWB) (7 questions) 
(Questions included as supplement w and described in the methods section). All four 
domains are to be scored simultaneously. There are 5 possible answers to all the 27 
questions, scored on a 5-point Likert-type scale from 0 (not at all), 1(a little bit), 2 (some 
what), 3 (quite a bit) and 4(very much). The responses to all the 27 questions are summed 
up (the negatively worded questions are coded in the reverse). In cases where individual 
questions are skipped, scores are prorated using the average of the other answers in the 
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scale. The total FACT-G score is obtained by summing individual subscale scores (PWB + 
EWB + SWB + FWB). The higher the FACT-G score better is the quality of life. 
 
Type of non-adherence 
 
Non adherence can either be intentional or non intentional. Using the DAMS (diagnostic 
adherence to medicines scale- described in detail in methods chapter and also chapter 4), 
we were able to determine the type of non adherence depending on the answers provided 
by the patients for the possible reasons for missing doses.  The patients could choose 
between 4 options and also had a blank space to provide reasons for missing tablets/ 
capsules of TKI in the last 7 days. The answers were codified as per the recommendations 
of the DAMS scale as intentional or non intentional non adherence. For example option 1 
was forgot to take, would be classified as non intentional non adherence, and whereas 
option 2- too tired and so missed a dose was intentional non adherence. We tried to see if 
the BMQ scale, especially concerns about medicines could predict for intentional non 
adherence.  
 
Statistical methods: 
 
 
Patient related factors including patients beliefs on medications (BMQ questionnaire), 
anxiety, depression and Quality of life has been analysed to see if they predicted for better 
adherence using the 4 adherence measures described in detail in chapter 4. Briefly the four 
adherence measures were visual adherence scale (VAS), Haynes et al question, Lu’s 
adherence scale and the diagnostic adherence to medicines scale (DAMS). The self 
reported adherence as measured by the 4 scales were divided into 4 categories as 
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described in detail in the previous chapter. Briefly the adherence from VAS, Lu’s and the 
DAMS were categorised as <80%, 81 to 90%, 91% to 98% and >98%. The missed doses 
reported by Haynes et al scale was categorised as no missed doses, >1 missed dose, >2 
missed doses and >3 missed doses. The adherence categories were the dependent variable 
and patient related factors were the independent variable in ordinal logistic regression. 
Patient related factors were analysed as both a continuous and a categorical variable.  
We also performed a second analysis where the predictive value of patient related factors 
on responses as defined by ELN was calculated using binary logistic regression.  The 
responses and their results are described in detail in chapter 4. Briefly, the responses were 
categorised into optimal, suboptimal and poor responses (failure). For the purposes of this 
study, the optimal and the suboptimal responses have been grouped together. In binary 
logistic regression, the responses were the dependent variable (failure vs. Optimal and 
suboptimal and the patient related factors were the independent variables).  Again the 
patient related factors were analysed as both a continuous and a categorical variable.  
We also tried to see if concerns (derived from the BMQ scale, necessity concerns differential 
coded as 1) could predict for intentional non adherence using binary logistic regression.  
VI.3 Results: 
 
 
VI.3.1 Description of Necessity and concerns of the patients 
 
 
Two hundred and eighty six patients (97%) completed the 10 point BMQ questionnaire. The 
median scores for the necessity scale was 21 (range 9-25). The median score for the 
concerns scale was 9 (range 5 to 23). The necessity concerns differential median score was 
10 (range -3 to 20). Two hundred and sixty seven (93%) patients felt their medicines were 
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necessary and it was important to them whereas 19 patients (7%) of the patients felt 
concerned about their medicines. 
 
Increasing concerns scores predicts adherence: 
 
The concerns scale was analysed as a continuous variable to look for a relationship with 
adherence measured by all 4 scales (VAS, Haynes scale, Lu’s Scale and DAMS). 
Higher concerns scores were not predictive of adherence by VAS (OR- 0.95, p=0.51). 
Similarly the scores were not predictive of missed doses by Haynes et al (OR- 0.25, 
p=0.348). Increasing concerns were predictive of increasing adherence by the Lu’s scale 
(OR-1.3, p<0.0001). The concerns score was not found to be predictive of adherence by 
DAMS (OR-0.944, p=0.63). Higher concerns scores were not predictive of poor clinical 
responses by the ELN guidelines (OR- 0.98, p=0.77) 
 
Necessity scores did not predict for adherence or clinical outcomes: 
 
Higher necessity scores were not predictive of adherence by VAS (OR- 0.92, p=0.48) or Lu’s 
scale (OR-0.94, p=0.35). Similarly increasing scores in the necessity scale was not 
predictive of adherence by Haynes (OR-1.06, p=0.59) or DAMS (OR- 0.88, p=0.11). Higher 
scores were not predictive of poor clinical responses either (OR-1.01, p=0.71).  
 
Relationship between necessity concerns scores with anxiety and depression 
 
Necessity scores were not predictive of anxiety (OR-0.95, p= 0.4), however higher scores 
were predictive of depression (OR- 1.07, p=0.05). On the other hand people with higher 
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scores for concerns were highly likely to be anxious (OR-1.37, p<0.0001) and depressed 
(OR-1.07, p=0.026).   
 
Necessity-concerns differential (N-C diff): 
 
N-C Diff, a continuous variable, was analysed for its predictive value in being able to predict 
adherence and clinical responses, also for its relationship to anxiety and depression. 
N-C diff was unable to predict responses by VAS (OR- 0.62, p=0.27), Haynes et al (OR- 
0.02, p=0.98) or DAMS scales (OR-0.11, p=0.874). However, a positive N-C diff (increasing 
concerns) was predictive of higher adherence by Lu’s adherence scale (OR- 1.08, p=0.025). 
N-C diff was not predictive of poor responses by ELN criteria (OR-0.97, p=0.95). N-C diff 
had an inverse relationship with anxiety (i.e. higher N-C diff correlated inversely with 
anxiety). There was no relationship between N-C diff and depression. 
 
N-C differential was not predictive of intentional non adherence: 
 
A total of 51 patients (17%) answered the question meant to categorise the non adherent 
patients into intentional or non intentional non adherence. Of this 33 patients (65%) 
indicated a reason that was classified as intentional non adherence and 18 patients (35%) 
indicated that their reason for non adherence was non-intentional. This was then compared 
with the 19 patients (N-C diff) who expressed concerns to their medications. There was no 
association between intentional non adherence and concerns to medicines as determined 
by the BMQ scale (p=0.6). Necessity (OR-0.8, p=0.5) and concerns scores (OR-0.92, p=0.6) 
separately did not predict for intentional non adherence either. 
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VI.3.2 Anxiety and depression: 
 
A total of 284 (96%) patients answered the questions regarding anxiety and depression. The 
median anxiety score was 12 (range 4 to 17) and depression score was 9 (range 3 to 15). 
Applying the recommended cut off of 8 for both the scales, a total of 256 patients (90%) 
were found to be anxious about their CML treatment and 143 (50%) patients appeared to be 
depressed. Forty eight percent of patients who were anxious were not found to be 
depressed whereas 95% of patients who were depressed were found to also be anxious 
(p=0.016).  
 
Relationship between anxiety and depression with adherence:  
 
 
Anxiety and depression scores were analysed as a continuous variable to predict for 
adherence as well as a categorical variable (using a cut of 8 for both). Odds ratios with their 
significance for all four adherence measures are outlined in Table 1 below. Anxious patients 
appeared to have lower adherence as estimated by Lu’s adherence scale and not by others, 
whereas depression was unrelated to adherence. 
 
Higher anxiety scores (i.e. anxious patients) as a continuous variable was unable to predict 
for adherence using VAS (OR- 0.32, p=0.559), nor as a categorical variable (using cut off 8 
for indicating anxiety), (OR-0.47, p=0.43). Similarly, higher scores in depression was unable 
to predict for adherence using VAS as a continuous variable (OR-0.12, p=0.26) or as a 
categorical variable using a cut off of 8 (OR- 0.35, p=0.27), [table 1]. 
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Increased anxiety levels among patients could not predict for missed doses (Haynes et al) 
either as a continuous scale (OR- 0.11, p=0.86) or as a categorical variable (OR-0.85, 
p=0.2). Depression does not appear to be related to patients missing doses of their TKI 
therapy (OR- 0.23, p=0.9) nor was the depression scores predictive of adherence by Haynes 
scale (OR- 0.1, p=0.92), [table 1].  
 
Anxious patients appeared to have lower adherence levels by Lu’s scale (OR- 0.911, 
p=0.034) and also increasing anxiety scores correlated with decreasing adherence (OR- 
1.04, p=0.009). Depression appeared to be unrelated to adherence by Lu’s categories (OR- 
0.29, p=0.8), [table 1].  
 
Anxiety (OR- 0.83, p=0.21) and depression (OR- 0.6, p=0.95) neither appeared to correlate 
with levels of adherence as determined by DAMS scale as a categorical variable nor as a 
continuous variable (table 1) 
 
Table 10- Relationship between anxiety and depression with the 4 adherence measures- showing p-vaues and 
odds ratios 
The second column shows comparison with the four adherence measures as a categorical and continuous variable with 
significance and odds ratios in third and fourth columns). 
 
 
Anxiety P values Odds Ratio 
Adherence measures  
VAS Continuous 0.62 0.32 
Categorical 0.43 0.47 
Haynes et al Continuous 0.86 0.11 
Categorical 0.2 0.85 
Lu’s adherence Continuous 0.009 1.04 
Categorical 0.034 0.29 
DAMS Continuous 0.94 0.4 
Categorical 0.21 0.83 
Depression P vaues Odds Ratio 
Adherence measures  
VAS Continuous 0.26 0.12 
 Page 105 of 171 
Categorical 0.27 0.35 
Haynes et al Continuous 0.92 0.1 
Categorical 0.94 0.23 
Lu’s adherence Continuous 0.88 0.3 
Categorical 0.27 0.29 
DAMS Continuous 0.95 0.6 
Categorical 0.97 0.1 
(VAS- visual adherence scale, DAMS- diagnostic adherence to medicines scale, P values 2 sided, 95% confidence interval, 
the highlighted values shows significant results) 
 
 
Anxiety and depression does not appear to be related to clinical responses  
 
Anxious patients did not appear to have any relationship with poor clinical response (OR- 
0.90, p=0.84). Similarly patients with higher depression scores also did not appear to predict 
poor clinical responses (OR- 1.3, p=0.4). 
 
VI.3.3 Quality of life (FACT-G): Description of answers 
Quality of life is based on 28 questions over 4 different sections. The total number is taken 
as the representative of the quality of life. Higher the number better is the quality of life. 
The median value for the FACT-G questionnaire is 88 (range 32 to 108). We divided the 
FACT-G values into 4 categories. The categories were 0 (1 to 27), 1 (28 to 54), 2 (55 to 81) 
and 3 (82 to 108). We analysed the relationship between quality of life with adherence, 
responses, anxiety, depression, necessity and concerns as both a continuous and 
categorical variable.  
 
Better quality of life predicts for higher adherence to TKI: 
 
When analysed as a continuous variable, QOL was predictive of adherence by VAS (OR- 
1.1, p=0.031) and missed doses by Haynes et al (OR = 1.5, p=0.033). Higher scores in QOL 
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was highly predictive of higher adherence by Lu’s scale (OR- 2.9, p<0.0001), however, QOL 
was not predictive of adherence by DAMS (OR- 0.20, p=0.065) 
When QOL is analysed as a categorical variable, the higher categories were highly 
predictive of better adherence by Lu’s adherence scale (OR- 2.8, p<0.0001). However the 
categorical divisions of QOL was not predictive of adherence by VAS (OR- 0.92, p=0.11), 
Haynes et al (OR- 0.8, p=0.22) or by DAMS (OR- 0.5, p=0.37). 
  
Better quality of life did not predict for poor responses: 
QOL when analysed as a continuous variable did not predict for responses as defined by the 
ELN criteria (OR- 0.2, p=0.22). Similarly, the categorical divisions of QOL was not predictive 
of responses either (OR- 0.45, p=0.18).  
 
Relationship between QOL and other patient related factors: 
 
Anxiety levels appeared to negative correlate with QOL with high significance (OR- 2.07, 
p<0.0001). This was true whether anxiety scores were analysed as a continuous or a 
categorical variable. On the other hand, there appeared to be no relationship between 
depression and QOL. Patients with concerns appeared to have an extremely poor QOL 
(OR- 6.9, p<0.0001) whereas patients who had higher necessity scores did not have bearing 
on their QOL (OR- 0.69, p=0.59). N-C differential did not appear to predict or have a 
relationship to patients QOL. 
 
VI.4 Discussion: 
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Necessity scores were found to be higher when compared to the concerns voiced by the 
patients regarding their medicines. When analysed in totality, nearly all patients felt their TKI 
therapy was necessary and very few patients had concerns regarding it (7%). When patients 
were concerned about their medicines, it appeared to have an effect on their adherence to 
TKI as well. An increase in concerns score by 1 predicted for a 2.5% increase in adherence 
levels as determined by Lu’s scale, this finding was particularly surprising, considering one 
would have expected to find an opposite result of decreasing adherence when patients are 
concerned about their medicines. The necessity scores on the other hand were unable to 
predict for adherence to therapy or clinical outcomes. The BMQ scale was developed to 
reflect the fact that when patients are concerned about their medicines, they are likely to 
have an intentional non adherence towards taking their TKI therapy. In our study, we found 
that necessity concerns differential, was unable to predict for intentional non adherence, 
however the N-C diff was able to predict for adherence by Lu’s scale. The self reported 
adherence by Lu’s appeared to correlate well with anxiety as compared to the other 3 
adherence measures. A possible explanation could be the number of patients deemed non 
adherent by Lu’s scale, which is much higher than those by the others. Also Lu’s questioning 
involved indirect means of determining self reported adherence as compared to the other 
three which included more direct questions relating to taking medications or missing them, 
hence possibly capturing more non adherent patients. Also it is worth noting that only 18 
patients were deemed to have concerns as per the BMQ scale, hence correlating this small 
number to the group of non adherent patients which were also small did not appear to be 
significant in the case of the three other adherence measures (VAS, Haynes et al and 
DAMS).  
We found in our study that when patients found their medicines to be necessary, they were 
likely to be depressed, but not anxious. Similarly, when patients had concerns about their 
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medications, they were both likely to be depressed and anxious about their life and 
treatment. The relationship between concerns with anxiety and depression appears to be 
logical one as patients who are worried about their medicines are likely to be anxious about 
their therapy and feel low in mood. Similarly, when patients think their medicines are 
extremely imperative and necessary to a good life, it could make them feel depressed that 
they are have to depend on it for ever and they are likely to be less anxious compared to 
patients who are worried about the possible consequences of their medications. 
Majority of the patients who participated in the study (90%) appeared to be anxious about 
their CML treatment whereas half the patients questioned appeared depressed. Majority of 
the depressed patients appeared to be anxious (p=0.01). These numbers appear to be in 
keeping with similar such studies involving patients with cancer and on long term therapies. 
What is striking to note is that even with advancements in TKI therapies and clinical 
outcomes with excellent overall survival in patients with CP CML, they still appeared anxious 
about their therapies. Perhaps communicating the current survival trends to patients may put 
their mind at ease and could possibly decrease their anxiety levels. Half the patients appear 
to be depressed, but this may not necessarily mean clinically evident depression, 
nonetheless, is a useful statistic for the treating physicians to consider recommending 
appropriate interventions if clinically obvious. 
Anxiety levels appear to be related to adherence to TKI therapy as measured by Lu’s 
adherence scale and not by other means. One would expect anxious patients to be more 
likely to be adherent to therapy, but anxiety levels may not always mean anxiety about the 
disease, but could also mean anxiety about the medications and its long term effects and 
potential implications. This may lead to the speculation that anxious patients may potentially 
miss doses leading to a form of intentional non adherence, however when analysed, there 
appeared to be no basis for such a conclusion. It is also possible that small sample size of 
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patient’s reasons for non adherence could potentially hide a true relationship between the 
two. A study with larger numbers could strengthen or refute this theory. Depression did not 
appear to have any relationship with adherence. Both anxiety and depression were not 
predictive of poor clinical outcomes. 
Patients in general appeared to have a good quality of life. The median value of the FACT-G 
questionnaire for 296 patients was 88 (range 32 to 108), with higher numbers predicting a 
better QOL. Better QOL was relate to better adherence as measured by VAS and missed 
doses (Haynes et al). The most significant association of better QOL with higher levels of 
adherence was by Lu’s adherence scale. QOL however did not appear to predict for clinical 
outcomes.  
Patients QOL seemed to be influenced by other patient related factors like anxiety and 
feeling concerned about their medication. The most significant association was between 
patients who had concerns about their medications and poor QOL (OR- 6.9). There was also 
a very strong relationship between anxious patients and poor quality of life. QOL however 
did not appear to be influenced by patients feeling depressed or by increased necessity to 
take their medications.  
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Chapter VII. Optimising intolerance by changing TKI therapy to minimise 
low grade side effects 
VII.1 Introduction 
Imatinib induces durable responses in the majority of the patients who receive this drug as 
first line therapy while in chronic phase, however a substantial proportion of patients have 
persistent low grade side effects that impair their quality of life112. We and others have 
shown that poor adherence to TKI therapy correlates with inferior clinical outcomes and side 
effects to therapy have been identified as one of the possible reasons for poor adherence to 
medication93, 99. Our group has also shown that the loss of complete cytogenetic responses 
occur due to poor adherence and intolerance is thought to play a significant role in it124. 
Cortes et al has shown that patients on nilotinib and imatinib had very little cross intolerance 
amongst them in a study of patients in a phase 2 clinical trial73. Although not formally shown 
outside this study it is generally acknowledged that TKI therapies have low cross intolerance 
amongst them and this thought was the reason behind our current study. We tried to use 
this strategy to minimize side effects by taking advantage of the low cross intolerance 
between different tyrosine kinase inhibitors (TKIs) and to change therapy in the presence of 
insidious low grade side effects. However, what was unclear was whether such a change in 
therapy can adversely affect response, or induce resistance and whether indeed eliminate 
the side effect.  Here we retrospectively report our experience in 57 patients who began 
treatment on imatinib and achieved complete cytogenetic response (CCyR) on imatinib as 
first line therapy. The patients then had their TKI changed solely on account of minor 
persistent side effects to second and third generation TKIs namely (nilotinib, dasatinib and 
bosutinib). We have tried to analyse the effect of changing TKI solely on the basis of side 
effects on clinical outcomes, mutations and subsequent development of side effects.  
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VII.2 METHODS 
Two hundred and seventy four patients with chronic phase CML who were treated at the 
Hammersmith hospital with first line imatinib therapy as described in chapter 2 formed the 
basis of this cohort. Fifty-seven patients of the 274 (20.8%) patients on imatinib attained 
CCyR and subsequently had their TKI therapy changed due to minor chronic (>6 months) 
low grade (Grade 1 to 2) side effects in the absence of any sign of resistance. The median 
age was 54 years (range 36-69) and 35 (62%) were male. Five (9%) patients had additional 
chromosomal abnormalities at diagnosis. The Sokal risk group distribution was 24 (42%) 
low, 20 (35%) intermediate and 13 (23%) high.  Thirty-seven patients received dasatinib 
second line, 19 nilotinib and 1 bosutinib. Seventeen of these patients subsequently changed 
to a third line TKI (14 patients to nilotinib and 3 to dasatinib) again due further intolerance 
and finally two of these 17 patients changed to a fourth line TKI (one patient to nilotinib and 
one to bosutinib). Dasatinib, nilotinib and bosutinib were administered as described by 
others. Patients gave informed consent for their clinical data to be reported. Minor side 
effects were defined as any side effect caused by the TKI therapy that persisted at grade I 
despite optimal care. Common toxicity criteria (CTC) were used to grade the side effects on 
the basis of guidance provided by NCCN129.  
BCR-ABL1 transcripts were measured in the blood at 6 to 12 week intervals using RTq-PCR 
as described previously in chapter 2130. Molecular responses (MR) were expressed 
according to the log reduction in the transcript level below the conventionally defined starting 
point of 100%131, 132. MR3 (equivalent to major molecular response) was defined as a 
transcript level ≤0.1% on the international scale. MR4.5 was defined as BCR-ABL1 ratio of 
0.0032% on the international scale provided copies numbers of the control was at least 
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40,000. Complete molecular response (CMR) was defined by the presence of two 
consecutive samples with no detectable transcripts and an ABL1 control >40,000 copies. 
Samples with an ABL1 control <10,000 were discarded. Samples obtained for RTq-PCR 
were also analyzed for KD mutations at the moment of changing therapy using direct 
sequencing as described in the methods chapter and when resistance therapy was 
suspected133.  
Statistics: 
The data was analysed using the statistical package SPSS statistics 20.0 (August 2012, 
SPSS Inc., Chicago, Illinois). Probability of remaining on therapy was calculated using the 
Kaplan-Meier method. The probabilities of molecular responses were calculated using the 
cumulative incidence (CI) procedure, whereby molecular responses were the events of 
interest and death and therapy discontinuation were the competitors. P values were 2 sided 
and 95% confidence interval was used.  
 
VII.3 RESULTS 
Patients received imatinib for a median of 44 months (range 16-135) before discontinuation.  
The median duration on 2nd line TKI therapy was 48 months (range 10 to 50). The median 
duration on third line therapy was 30 months (range 7-42). Two patients eventually changed 
to a fourth TKI (bosutinib n=1, nilotinib n=1) due to side effects. At the time of starting 
second line TKI, 2 patients were in CMR, 3 in MR4.5, 25 in MR3 and 27 in CCyR (but not in 
MR3 or better). During the follow up there was no loss of response, progression to advanced 
phase or CML related deaths. Two patients died from non-CML related causes. 
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VII.3.1 Second line TKI is generally well tolerated and there is minimal cross 
intolerance following change of TKI 
Table 1 shows the dominant grade I side effects on imatinib that motivated the initial change 
of therapy; the commonest were arthralgia (16%), dermatologic events such as rash and 
pruritus (16%), and headache (14%). 
Table 11- Grade I side effects on imatinib therapy that led to treatment change in the 57 patients 
 
 
 
 
 
 
 
 
 
 
 
 
* LFTs: Liver function tests 
Twenty-five (44%) patients developed side effects on the second line drug.  The commonest 
side effects were pleural effusion (n=9, 36%) and headache (n=2, 8%). The side effects 
were grade II-IV in 5 of these patients (pleural effusion n=4 and retinal hemorrhage n=1) and 
necessitated change of therapy. In the remaining 20 patients the side effects were grade I 
and 12 of these patients changed TKI (Table 2).  Eight of these patients who had grade I 
Side effect Frequency n (%) 
Arthralgia 9 (15.8) 
Skin Rash 9 (15.8) 
Nausea 6 (10.5) 
Diarrhoea 5 (8.8) 
Asthenia 6 (10.5) 
Head ache 8 (14.0) 
Muscle cramps 7 (12.3) 
Elevated LFTs* 4 (7.0) 
Peripheral edema 3 (5.3) 
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side effects on second line TKI elected not to changed therapy as the side effects were very 
mild and the patients perceived them as insignificant and therefore requiring no action.  
These side effects were skin rash (n=2), muscle cramps (n=1), asthenia (n=3) and arthralgia 
(n=2). Only four patients developed the same side effect on second line TKI that they had 
experienced on imatinib (muscle cramps and arthralgia).   
As explained above 17 patients changed to third line therapy (5 patients with grade II-IV side 
effects and 2 patients with grade I). On third line TKI, 12 (71%) patients become totally free 
of side effects. Two of the remaining five patients changed to a fourth line drug (recurrent 
pleural effusion and peripheral occlusive arterial disease), and are now asymptomatic. The 
remaining three patients elected not to change treatment as again the side effects were very 
minor and perceived by the patients as negligible (rash, pruritus and headache). Table 2 
details side effects that warranted change of therapy and their outcome.  
Table 12- Management and outcome of the side effects that occurred on the different TKIs 
SIDE EFFECTS 
ON IMATINIB (n) 
TKI 
CHANGE 
(n) 
OUTCOME (n) 
Arthralgia (9) 
Dasatinib (4) 
No recurrence (3) 
Significantly reduced 
(1) 
Nilotinib (5) 
No recurrence (3) 
Significantly reduced 
(2)  
Skin Rash (9) Dasatinib (6) No recurrence (6) 
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 Nilotinib (2) No recurrence (2) 
Bosutinib (1) No recurrence (1) 
Nausea  (6) 
Dasatinib (4) No recurrence (4) 
Nilotinib (2) No recurrence (2) 
Diarrhoea (5) 
Dasatinib 
(2), 
No recurrence (2)                   
Nilotinib (3) No recurrence (3)                   
Asthenia (6) Dasatinib (6) No recurrence (6) 
Headache (8) 
Dasatinib (5) No recurrence (5) 
Nilotinib (3) No recurrence (5) 
Muscle cramps (7) 
Dasatinib (5) No recurrence (5) 
Nilotinib (2) 
No recurrence (1) 
Recurrence (1) 
Elevated LFTs* (4) Dasatinib (4) No recurrence (4) 
Peripheral edema 
(3) 
Dasatinib (1) No recurrence (1) 
Nilotinib (2) No recurrence (2) 
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Table 3 continued 
* 
LFTs: Liver function tests; 
SIDE EFFECTS ON 
DASATINIB (n) 
TKI 
CHANGE 
(n) 
OUTCOME (n) 
 
Pleural effusion (9) 
Nilotinib (8) 
No recurrence (7) 
Recurrence (1) 
Bosutinib (1) Recurrence (1) 
Diarrhoea (1) Nilotinib (1) No recurrence (1) 
Asthenia (1) Nilotinib (1) No recurrence (1) 
Headache (1) Nilotinib (1) No recurrence (1) 
Muscle Cramps (1) Imatinib (1) No recurrence (1) 
Peripheral oedema 
(1) 
Nilotinib (1) No recurrence (1) 
Retinal 
haemorrhage  (1) 
Nilotinib (1) No recurrence (1) 
SIDE EFFECTS ON NILOTINIB (n) 
Muscle cramps (1) Imatinib (1) No recurrence (1) 
PAOD**  (n=1) Bosutinib (1) No recurrence (1) 
SIDE EFFECTS ON BOSUTINIB (n) 
Pleural effusion (1) Nilotinib (1) No recurrence (1) 
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 ** PAOD; Peripheral arterial occlusive disease 
 
VII.3.2 Patients who change TKI therapy on account of persistent minor side effects 
sustain or improve their previously attained response 
All 57 patients had further reduction in BCR-ABL1 transcript levels following change of 
therapy. The median transcript level at the time of changing was 0.29% (range 0.09% to 
3.5%) and the median reduction in 12-month BCR-ABL1 transcript level after change in TKI 
was half log (range 0.2-1.5). Two patients were in complete molecular response (CMR) prior 
to change and maintained CMR thereafter. On second line therapy, 14 patients achieved 
CMR, 13 MR4.5 and 15 MR3.  The 1- and 4-year cumulative incidence (CI) of MR3 for the 
38 who had not achieved MR3 at the point of change was 78% and 94% respectively. 
Similarly the 1-and 4-year CI of MR4.5 was 30% and 48% respectively and the 1 and 4 year  
CI of CMR was 8% and 24% respectively. The probability of remaining on second line 
therapy at 48 months after switching TKI was 72.4%. 
The 17 patients who changed to a third line TKI also attained further reduction in their BCR-
ABL1 transcript numbers. The median reduction in the BCR-ABL1 transcript level obtained 
12 months after change to third line therapy was 1 log (range 0.1-2). Two patients were 
subsequently changed to a fourth TKI due to side effects (bosutinib n=1, nilotinib n=1) and 
also continued to have further reduction in their transcript levels. When considering the 
global outcome of all 57 patients that changed therapy, the 4-year probability of being in 
MR3, MR4.5 and CMR were 98.2%, 52.1% and 26.6% respectively.  
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VII.3.3 Repeated change of TKI therapy does not seem to increase the frequency of 
kinase domain mutations 
Patient samples were tested for the presence of BCR-ABL1 kinase domain mutations. Our 
institutional practice has changed with time but samples were tested at least at the moment 
of changing TKI therapy and in case of doubling of BCR-ABL1 ratio (provided that there 
were more than 10 BCR-ABL1 transcripts). In the analysis performed at the moment of 
changing therapy we unexpectedly identify one kinase domain mutation (D276G) in a patient 
receiving first line imatinib. The patient had not had any prior increase in the transcript level 
and the mutation disappeared with the change of therapy. We performed an additional 143 
mutation analyses during second or subsequent lines on account of increasing transcript 
levels. In all these cases the mutation analysis was negative and the transcript level 
subsequently declined without intervention. 
 
VII.4 DISCUSSION 
 
Low grade side effects induced by TKI are often dismissed by clinicians used to dealing with 
much more toxic regimens. Patients may also often fail to bring the persistence of minor side 
effects to the attention of their treating physicians as some times patients feel that the side 
effects are a very small price to pay for not succumbing to their leukaemia. However these 
side effects can have a significant impact on the quality of life of patients, particularly as 
most patients are likely to require lifelong therapy. However, minor persistent side effects 
may have clinical consequences other than poor quality of life. We and others have shown 
that side effects are often the reason for poor adherence and poor adherence may lead to 
loss of response. For example in a study performed at the Hammersmith Hospital the 2-year 
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CI of loss of CCyR for adherent and not adherent patients was 1% vs 36% (p<0.0001).8 For 
these reasons it is important to develop strategies that are aimed at minimizing the side 
effects suffered by patients.  
In this work we have shown that by proactively changing TKI therapy, we were able to free 
the majority of the patients from low grade chronic side effects (Figure 1). Forty-six (81%) 
patients become totally asymptomatic and an additional 11 patients (19%) had their side 
effects reduced to a point where the patients themselves considered that no further 
intervention was necessary. Thus all patients were liberated from minor persistent side 
effects. Most of the patients’ side effects resolved with the first change of medication, but 17 
(30%) required one or two additional changes. In the majority of the cases the second or 
subsequent changes of therapy were motivated by the occurrence of a different side effect 
rather than by the persistence of the original one. These new side effects, although 
sometimes more severe, were reversible or easy to manage in all cases.    
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Figure 8- Details of the patient outcome through  different lines of therapy and the effect of change of treatment on 
the side effects 
Negligible side effect indicates a grade I side effect, perceived as insignificant by the patient and not 
requiring intervention. 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, all patients improved their molecular response as noted by a further decrease 
in BCR-ABL1 transcript levels. In fact, the probability of being in MR3 or MR4.5 4 years after 
discontinuing imatinib was very high, namely 98.2% and 52.1% respectively. It is possible 
that this improved response was due to the greater efficacy of the 2G-TKI in comparison to 
imatinib, but we also showed improvement in those patients who changed from one second 
generation drug to another. We speculate that by reducing the side effects we were able to 
improve adherence to medication which also may have impacted on the response.  
It is theoretically possible that repeated changes of therapy may lead to the development of 
resistance. We did not observe this; during the follow up no patient developed resistance, in 
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fact all the patients improved their responses. We also carefully monitored patients for the 
development of BCR-ABL1 kinase domain mutations and none that could be attributed to a 
change of therapy was detected. We conclude that changing therapy on account of 
persistent minor side effects is an effective and safe therapeutic option. 
The impact of carrying on with imatinib in the long run may have produced similar clinical 
responses as the change in TKI therapy, but with the cost of patients putting up with chronic 
low grade side effects. This can only be known if a prospective study was done with 2 arms; 
one changing on account of side effects and the other remaining on the same TKI therapy. 
To truly validate the finding that there would have been no long term repercussions following 
change due to intolerance, one would have to conduct a larger study. The fact that if 
subsequently the patient needed a change in therapy for resistance, there may not be an 
option left because of an earlier change. But the argument in favour of an earlier change is 
that you have already changed over to a stronger TKI and hence the chance of a resistance 
in the future becomes extremely low and as per our findings although with a small cohort 
had a follow up for close to 8 years and we did not find any degree of resistance or new 
mutations.  
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Chapter VIII. Conclusion 
 
TKI therapy has revolutionised the management of CP CML patients. Beginning with 
imatinib, the subsequent second and third generation TKI’s have begun to improve the 
already excellent responses achieved with imatinib therapy. The landmark IRIS trial at the 
latest update showed the OS considering only CML related deaths to be well in excess of 
90%. With improving survival rates, strategies for pursuing newer therapeutic options were 
beginning to climb down the ladder of importance whereas research into methods to 
improve outcomes using existing therapies were beginning to gain momentum. A number of 
areas which could potentially be tapped to improve outcomes have been explored in the last 
few years.  
The importance of early molecular milestones in determining long term outcomes has been 
shown by us and a number of groups in patients on imatinib, dasatinib and nilotinib. Marin et 
al showed that patients who attain Bcr-Abl transcripts of less than 9.84% at 3 months and 
1.67% at 6 months have a better OS, PFS and higher CI of attainment of cytogenetic and 
molecular milestones compared to patients who fail to attain them. In this study we tried to 
combine the 3 and 6 month cut offs to identify poor risk patients. We showed that patients 
who attained the 3 and 6 month milestones as well as patients who attained the 3, but failed 
the 6 month milestone did equally well and had similar outcomes in terms of OS, CI of CCyR 
and CMT rates at 8 years. We also showed that the patients who failed to attain the 3 month 
milestone of 9.84%, but attained the 6 month cut off of 1.67% did equally badly as the group 
of patients who failed to achieve both milestones. In this way, we have added to the 
importance of early molecular monitoring by showing that patients who attain the 3 and 6 
month cut offs are the ones who are likely to have the best outcomes and that patients do 
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not improve their outcomes even if they attain the 6 month milestone after failing the 3 
month cut off. We propose that a single measurement of Bcr-ABL transcripts at 3 months is 
good enough to identify patients who are likely to do badly.  
Another key area of interest is adherence to TKI therapies and we along with others have 
shown that adherence is important to achieving molecular milestones and that lack of 
adherence contributes to loss of existing cytogenetic responses. The main draw backs of the 
existing methodologies are either a prohibitive cost or lack of standardisation to being 
extremely labour intensive. We have showed that self reported measures are effective in 
identifying non adherence and correlates with clinical outcomes.  
The four self reported adherence measures (Visual adherence scale, Haynes scale, Lu’s 
modified adherence scale and the diagnostic adherence to medicines scale) correlate well 
with each other and are able to predict poor responders. Adherence cut offs <95%, <90%, 
85% and <80% all correlated with poor clinical responses and the cut off < 80% was 
identified to be the best predictor. Similarly with the Haynes scales, increasing numbers of 
missed doses from 1 to >3 all showed good correlation with poor responders with the 
missed doses >3, the best predictor. In the Lu’s scale cut offs <95% and <90% were only 
significant and <90% being the best predictor of poor responses. In the DAMS scale all the 
four adherence cut offs (<95%, <90%, <85% and <80%) were significant with the 85% cut of 
being the best predictor.  
The best adherence cut offs for identifying poor responders varied between the different 
scales. This could be down to the varying methods used to identify adherence in the four 
methods. Haynes scale which is based on the number of tablets missed in the last 7 days 
was found to be the best of all the four self reported measures in identifying poor 
responders.  
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Patients whose day to day routines remained unaffected by CML and its treatment were 
found to have the best adherence to TKI therapy. Patients in general felt their 
communications with their physician was good. However nearly a third of the patients felt it 
was ok to miss an occasional dose and a similar number mentioned that they have never 
been told by their HCP that they need to take all their tablets and they may not do as well if 
they did not. Majority of the patients in the study did not use the internet to know about CML 
or engage with the patient support groups and this was uniform across age groups. The 
patients had no problems in terms of swallowing or physically taking the pills.  
On analysis of the individual questions, 4 out of a total of 30 were found to have 
independent predictive value in multivariate analysis, Someone helps me with managing my 
treatment at home, My daily routine changed a lot when I started my current CML medicine, 
I found it easy to adapt to the routine of taking my current medicine and it will NOT affect my 
response if I miss the occasional dose of medicine. These 4 questions were found to 
correlate very well with non adherence and hence can be used as surrogate markers in an 
out-patient setting without directly having to ask patients if they missed taking their pills. To 
apply these into clinical practice requires further validation in prospective trials. 
Majority of the patients felt their CML medications were necessary and very few felt they had 
concerns regarding their treatment. The small number of patients with concerns had 
decreased adherence as compared to patients with increased necessity. The BMQ scale did 
not predict for intentional non adherence as had been suggested by previous reports. Nearly 
all patients (90%) appeared to be anxious and half of them depressed. The anxious patients 
appeared to have a lower adherence as determined by Lu’s scale and it is possible this 
could be due to patients being anxious about the effects of long term effects of treatment 
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with TKI. Patients with higher QOL appeared to have better adherence to therapy and poor 
QOL correlated with patients being anxious and concerned about their CML treatment. 
Intolerance to therapy has been shown to contribute to poor adherence to therapy and 
subsequently inferior outcomes. Low grade chronic side effects are present in a number of 
patients on TKI therapy and it interferes with their QOL. We have shown that it is possible to 
change TKI therapy when patients are in cytogenetic remission with low grade side effects 
and it leads to a near complete resolution in most patients. All the patients improved upon 
their previously attained molecular responses and none developed resistance or mutations. 
In this way it is possible to ameliorate chronic low grade side effects to improve tolerability 
and ultimately compliance to therapy.  
VIII.1 Future Directions: 
The main areas where future work could be undertaken based on the findings of this study 
would be a prospective randomised trial to see if switching or altering therapy at 3 or six 
months leads to improved outcomes. A number of trials are looking to switch therapy at 
these early time points to improve outcomes but it remains to be seen if the failure to meet 
the 3 month milestone is in fact a poor risk group of patients who may do badly anyway. 
There is a school of thought that the patients who fail the 3 month milestone might represent 
a biologically poor risk group and hence identifying them early could help in rationalising 
appropriate therapies for them. 
Adherence can be tricky to measure in day to day clinics, hence the use of self reported 
measures assume significance as they are cheap and effective methods to identify non 
adherence and also they can be used repeatedly over a period of time to build a patterns of 
non adherence that be addressed. Tailored and patient specific interventions to tackle 
intentional and non-intentional non adherence needs to be developed. More needs to be 
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done to educate patients and other healthcare professionals involved in the care of CML 
patients on the impact of poor adherence. The simple questionnaire can be used in a variety 
of settings to determine non adherence. With the cancer treatment going towards targeted 
oral therapies, such tools can be invaluable in addressing the problems arising due to non 
compliance in a number of malignancies. Also such tools can be tried in non malignant 
settings such as oral anticoagulants where compliance can be vital in short acting drugs.  
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Appendix 1: Questionnaire study (Questionnaire) 
ID          
Study no.________ 
Date _____ 
Hospital 
  
 
• Please think about the medicine that you have been prescribed for your chronic myeloid leukaemia (CML), 
when answering the following questions. 
• The questions all are examples of what other patients with CML have told us they experience and how they 
manage their treatment.  
• There are no right and wrong answers; we are interested in your personal views and experiences. 
• Remember your answers are anonymous, meaning that no one will link your name to your answers. 
• Please seal in your answers in the envelope provided. This is to ensure or doctors and nurses will 
not read your responses. All your answers are completely confidential. 
 
Thank you for taking time to answer these questions! 
 
TREATMENT INFORMATION 
 
1) What medicine have you been prescribed for your chronic myeloid leukaemia (CML), please 
indicate by ticking the right box: 
Imatinib (Glivec)  Nilotinib (Tasigna)  Dasatinib (Sprycel) 
Bosutinib    Other, please specify________________________ 
 
2) How much medicine have you been prescribed? 
a) How many tablets/capsules have you been asked to take per day? 
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_________________________ 
b) How much is your dose in milligrams (mg) per day? 
 
_______________mg 
 
3) How many times per day do you take your medicine?  
Once / day Twice / day Three times / day   
Other, please specify__________________________ 
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4) When you were first prescribed your CML medicine, did you take a different dose to what you 
do now? 
YES  NO 
 
a) If YES, how many tablets/capsules were you initially asked to take per day? 
 
_________________________ 
b) If YES, how much were your previous dose in milligrams (mg) per day? 
 
_______________mg 
 
5) What MONTH and YEAR were you born? 
 
_____________________________________ 
 
6) What MONTH and YEAR where you diagnosed with CML? 
 
_____________________________________ 
 
 
7)  What MONTH and YEAR did you start your current CML treatment? 
 
_____________________________________ 
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8) Did you receive any treatment for your CML before starting on your current therapy? 
YES  NO 
 
a. If YES, please name the treatment you received previously. 
 
_________________________________________________________ 
 
_________________________________________________________ 
 
 
 
 
9) Are you prescribed any other medicines at this point in time in addition to your CML treatment? 
YES  NO 
 
a. If YES, how many other medicines are you prescribed (you only need to say the number 
of different medicines you take, NOT the names). 
 
______________________________________________________________ 
 
b. If YES, how many times per day do you take your medicines? 
 
______________________________________________________________ 
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Please turn page 
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• Please indicate the extent to which you agree or disagree with each statement below by circling the 
appropriate answer. 
 
 DAILY ROUTINE 
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1 My mealtimes have NOT changed 
much since I started taking my 
current medicine… 
1 2 3 4 5 
2 Someone helps me with managing 
my treatment at 
1 2 3 4 5 
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home........................................ 
3 My daily routine changed a lot when I 
started my current CML 
medicine…............. 
1 2 3 4 5 
4 I found it easy to adapt to the routine 
of taking my current 
medicine........................... 
1 2 3 4 5 
5 I travel for a long time to get to my 
CML appointments at the 
hospital......................... 
1 2 3 4 5 
 COMMUNICATION  
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e
e 
6 My doctor has spoken to me about 
how to manage side effects from my 
current CML 
medicine………………………………
………. 
1 2 3 4 5 
7 My doctor does NOT generally ask 
me about how I am getting on with 
taking my 
medicine…..........................................
.......... 
1 2 3 4 5 
8 My doctor has explained to me how 
to manage my current CML 
treatment.............. 
1 2 3 4 5 
9 My doctor has told me to take my 
medicine exactly as 
prescribed.................................... 
1 2 3 4 5 
1
0
I generally do NOT understand what 
my doctor says about my CML 
treatment........... 
1 2 3 4 5 
1
1
If I do NOT understand what my 
doctor says I generally ask the doctor 
to explain..... 
1 2 3 4 5 
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1
2
My doctor does NOT listen to what I 
have to 
say………………………………………
……... 
1 2 3 4 5 
1
3
It is generally the nurse who gives me 
advice on how to manage my CML 
treatment.............................................
......... 
1 2 3 4 5 
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1 It is generally the pharmacist who 1 2 3 4 5 
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4 gives me advice on how to manage 
my CML 
treatment………………………………
……… 
1
5
It is generally my doctor who gives 
me advice on how to manage my 
CML 
treatment………………………………
……… 
1 2 3 4 5 
 INTERNET AND SUPPORT 
NETWORKS 
     
1
6
I search the internet to find 
information about my 
CML…………………..................... 
1 2 3 4 5 
1
7
I use online CML internet forums / 
networks 
…………………………………………
………. 
1 2 3 4 5 
1
8
I am in contact with CML patient 
advocacy 
groups…………………………………
……….  
1 2 3 4 5 
1
9
I have used CML patient support 
services (e.g. councillor / 
1 2 3 4 5 
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psychologist) ……………… 
2
0
I have been in contact with support 
person who is also a CML 
patient…………………… 
1 2 3 4 5 
 TAKING THE MEDICINE 
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2
1
I find it difficult to swallow my CML 
medicine..............................................
......... 
1 2 3 4 5 
2 I sometimes forget to take my 1 2 3 4 5 
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2 medicine....... 
2
3
The doctors have said that it does 
NOT matter if I miss the occasional 
dose............. 
1 2 3 4 5 
2
4
I find it difficult to take the medicine 
out of the 
packaging............................................
... 
1 2 3 4 5 
2
5
Sometimes I stop taking my CML 
medicine for some reason for a few 
days without consulting my 
doctor…………………………. 
1 2 3 4 5 
2
6
It will NOT affect my response if I 
miss the occasional dose of 
medicine........................ 
1 2 3 4 5 
2
7
I keep my medicine in a box with little 
compartments for timings and days of 
the 
week……………………………………
……… 
1 2 3 4 5 
2
8
I was off my medicine for some time 
and it did NOT affect my CML 
much...................... 
 please tick if you have never been 
1 2 
 
3 
4 5 
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off your medicine 
2
9
I think it is ok to miss a few doses 
now and 
again...................................................
.......... 
1 2 3 4 5 
3
0
I sometimes decide to skip doses of 
my current CML 
medicine………………………. 
1 2 3 4 5 
3
1
I use an alarm to help me remember 
to take my CML 
medicine......................................... 
1 2 3 4 5 
3
2
 I would feel worried if I missed a 
dose........ 
1 2 3 4 5 
3
3
I have been told that I need to take 
every single dose or my treatment 
might NOT 
work……………………………………
………. 
1 2 3 4 5 
 
NOTE: Please only answer N1-N6 if 
you take NILOTINIB (TASIGNA) 
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N
1
I find it difficult to 
fast.................................... 
1 2 3 4 5 
N
2
I sometimes forget to 
fast............................. 
1 2 3 4 5 
N
3
If I have NOT managed to fast I skip 
my 
dose....................................................
.......... 
 please tick if you always manage to 
fast. 
1 2 3 4 5 
N
4
I think it is better to eat when I am 
hungry than to always fast exactly as 
they tell me... 
1 2 3 4 5 
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N
5
I take my Nilotinib even if I have NOT 
been 
fasting…………………………………
……….  
 please tick if you always manage to 
fast 
1 2 3 4 5 
N
6
I use a ‘dosing wheel’ to help me 
decide when it is time to take my 
Nilotinib and when to 
fast.................................................. 
1 2 3 4 5 
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1) Do you have any other comments about what makes it MORE DIFFICULT for you to take your 
CML medicine? 
 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 ________________________________________________________________________ 
2) Do you have any other comments about what makes it EASIER for you to take your CML 
medicine? 
 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 
 
Please turn page 
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• We would now like to ask you about your personal views about your medicine. 
• These are statements other people have made about their medicine. 
• Please indicate the extent to which you agree or disagree with them by circling the appropriate number. 
• There are no right or wrong answers. We are interested in your personal views. 
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My health, at present, depends on my 
CML 
medicine...................................................
1 2 3 4 5 
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......... 
Having to take my CML medicine worries 
me... 
1 2 3 4 5 
My life would be impossible without my 
CML 
medicine...................................................
......... 
1 2 3 4 5 
Without my CML medicine I would be 
very ill… 
1 2 3 4 5 
I sometimes worry about long-term 
effects of my CML 
medicine.............................................. 
1 2 3 4 5 
My CML medicine is a mystery to 
me............... 
1 2 3 4 5 
My health in the future will depend on my 
CML 
medicine...................................................
......... 
1 2 3 4 5 
My CML medicine disrupts my 
life..................... 
1 2 3 4 5 
I sometimes worry about becoming 
dependent on my CML 
medicine......................................... 
1 2 3 4 5 
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My CML medicine protects me from 
becoming 
worse........................................................
......... 
1 2 3 4 5 
 
 
 
 
 
Please turn page 
 
• These questions ask about how you are getting on with taking your medicines. We know that 
many patients at times miss or change doses of their medicines. Some forget, others have 
various problems taking their medicine, and yet other patients adapt their treatment so it better 
fits in with their life. Please answer the following questions the best you can. The information 
will help us to understand how we can better adjust individual patients’ treatments to suit their 
life.  
• Although there is some repetition in the following questions, please answer all of the questions 
best you can. 
 
1) People often miss taking doses of their CML medicine, for a whole range of reasons. 
     Thinking of the last 7 days: 
 
HOW MANY tablets/capsules of your CML medicine have you MISSED taking in the last 7 DAYS? 
 ___________________________________________________________________________ 
If you HAVE MISSED tablets/capsules, GO TO question 2. If not, please GO TO question 3 
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2) Here are examples of reasons other people have given for missing doses of their CML 
medicine. THINKING OF THE DOSES YOU MISSED IN THE LAST 7 DAYS, which of the 
following statements best describe what happened (you can choose more than one option)? 
 
 I decided not to take it       
 I forgot to take it        
 I was unable to take it       
 The doctor told me not to take it     
 Other (please specify) ________________________________________ 
 
3) People often take more of their medicine than has been prescribed.  
Thinking of the last 7 days:  
 
How many EXTRA tablets/capsules did you take in the last 7 DAYS? 
 ___________________________________________________________________________ 
If you HAVE taken extra capsules GO TO question 4.  If not, please go to question 5. 
 
Please turn page 
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4) Here are examples of reasons other people have given for taking extra CML medicine. 
THINKING OF THE EXTRA DOSES YOU HAVE TAKEN IN THE LAST 7 DAYS, which of the 
following statements best describe what happened (you can choose more than one option)? 
 
 I decided to take more      
 I accidentally took more      
 The doctor told me to take more    
 Other (please specify) __________________________________ 
 
5) In the last 7 days did you take all your CML medicine? 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
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 6) Rate your ability to take all your CML medicine as prescribed in the last 7 days? 
 Very poor 
 Poor 
 Fair 
 Good 
 Very good 
 Excellent 
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7) Put a cross on the line below at the point showing your best guess about how much of 
your CML medicine you have taken in the last 7 days.  
For example, 0% means you haven’t taken any medicine, 50% means you have taken half of your 
medicine and 100% means you have taken every single dose of medicine. If you have taken more 
medicine than you have been prescribed it means you have taken more than 100%. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please turn page 
 
0% 10 20 30 40 50% 60 70 80 90 100% 110 
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Below is a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your response 
as it applies to the past 7 days. 
 
 
PHYSICAL WELL-BEING N
o
A
 
S
o
Q
u
V
e
I have a lack of energy ................................................................0 1 2 3 4 
I have nausea .............................................................................0 1 2 3 4 
Because of my physical condition, I have trouble 
meeting the needs of my family ..................................................
 
0
 
1 
 
2 
 
3 
 
4 
I have pain ..................................................................................0 1 2 3 4 
I am bothered by side effects of treatment ................................ 0 1 2 3 4 
I feel ill ........................................................................................0 1 2 3 4 
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I am forced to spend time in bed .................................................0 1 2 3 4 
 
SOCIAL/FAMILY WELL-BEING 
 
N
o
A
 
S
o
Q
u
V
e
I feel close to my friends .............................................................0 1 2 3 4 
I get emotional support from my family ................................ 0 1 2 3 4 
I get support from my friends ......................................................0 1 2 3 4 
My family has accepted my illness ..............................................0 1 2 3 4 
I am satisfied with family communication about my 
illness .........................................................................................
 
0
 
1 
 
2 
 
3 
 
4 
I feel close to my partner (or the person who is my 
main support) .............................................................................
 
0
 
1 
 
2 
 
3 
 
4 
Regardless of your current level of sexual activity, 
please answer the following question. If you prefer 
not to answer it, please mark this box           and go 
     
I am satisfied with my sex life ..................................................... 0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it 
applies to the past 7 days. 
 
 
EMOTIONAL WELL-BEING N
o
A
 
S
o
Q
u
V
e
I feel sad ..................................................................................... 0 1 2 3 4 
I am satisfied with how I am coping with my illness ..................... 0 1 2 3 4 
I am losing hope in the fight against my illness ........................... 0 1 2 3 4 
I feel nervous .............................................................................. 0 1 2 3 4 
I worry about dying ................................................................ 0 1 2 3 4 
I worry that my condition will get worse ................................ 0 1 2 3 4 
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FUNCTIONAL WELL-BEING 
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I am able to work (include work at home) ................................ 0 1 2 3 4 
My work (include work at home) is fulfilling ................................ 0 1 2 3 4 
I am able to enjoy life ................................................................ 0 1 2 3 4 
I have accepted my illness .......................................................... 0 1 2 3 4 
I am sleeping well ................................................................ 0 1 2 3 4 
 Page 160 of 171 
I am enjoying the things I usually do for fun ................................ 0 1 2 3 4 
I am content with the quality of my life right now ......................... 0 1 2 3 4 
 
 
 
Please turn page 
 
 Page 161 of 171 
Emotions play an important part in most illnesses. These questions are designed to help the 
researchers know how you feel. Read each item and underline the reply which comes closest to how 
you have been feeling in the past week. 
 
Don’t take too long over your replies; your immediate reaction to each item will probably be more 
accurate than a long thought out response. 
 
I feel tense or 'wound up': 
Most of the time 
A lot of the time 
From time to time, occasionally 
Not at all 
I still enjoy the things I used to 
enjoy: 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
I get a sort of frightened feeling as 
if something awful is about to 
happen: 
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Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn't worry me 
Not at all 
I can laugh and see the funny side 
of things: 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all 
 
Worrying thoughts go through my 
mind: 
A great deal of the time 
A lot of the time 
From time to time, but not too 
often 
Only occasionally 
I feel cheerful: 
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Not at all 
Not often 
Sometimes 
Most of the time 
I can sit at ease and feel relaxed: 
Definitely 
Usually 
Not Often 
Not at all 
I feel as if I am slowed down: 
Nearly all the time 
Very often 
Sometimes 
Not at all 
I get a sort of frightened feeling like 
'butterflies' in the stomach: 
Not at all 
Occasionally 
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Quite Often 
Very Often 
 
I have lost interest in my 
appearance: 
Definitely 
I don't take as much care as I 
should 
I may not take quite as much 
care 
I take just as much care as ever 
I feel restless as I have to be on the 
move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
I look forward with enjoyment to 
things: 
As much as I ever did 
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Rather less than I used to 
Definitely less than I used to 
Hardly at all 
I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
I can enjoy a good book or radio or 
TV program: 
Often 
Sometimes 
Not often 
Very seldom 
Please turn page 
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• The following questions ask a few personal details about you in order for us to 
get a better understanding of the background of the patients included in this 
study. 
 
1. Who else lives in your household? Please tick the appropriate boxes (as 
many that apply). 
I live alone  Partner/spouse  children under age of 18 
Children over age of 18  
my parents  my spouse’s/partner’s parents  my/my spouse’s/partner’s 
grandparents  
flatmate/lodger  Other, please specify____________________  
 
 
2. What is your ethnic group? 
 
A White      B Mixed / multiple ethnic groups 
British      White and Black Caribbean 
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Any other white background, write below  White and Black African 
____________________________________ White and Asian 
Any other Mixed / multiple ethnic 
background,  
write below 
      
 ______________________________ 
C Asian      D Black / African / Caribbean / 
Black European 
Indian      African 
Pakistani      Caribbean 
Bangladeshi     Any other Black / African / 
Caribbean background 
Chinese      write below 
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Any other Asian background, write below 
 ______________________________ 
________________________________    
E Other ethnic group 
Arab 
 Any other ethnic group, write below 
___________________________________ 
 
3. Do you sometimes worry that you will not have enough money to pay for 
your CML treatment? 
 
 Yes   No   I don’t have to pay for my treatment   
 
 
4. What category best described your occupation, please tick ALL boxes that 
apply: 
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 I work fulltime   I work part-time     I look after 
a household  
 I am retired  I am actively looking for work  I am unemployed 
 I am a student        
 
 
5. What category best describes your HOUSEHOLD’s annual income 
received from salary or wages, or pensions, benefits and allowances, before 
deducting tax? 
 
 £10 000 or less   £10 000 – £14 999  £15 000 – £19 999  
 £20 000 – £24 999  £25 000 – £34 999  £35 000 – £49 999  
 £50 000 – £69 999  £70 000 or more   
 
 
6. Which of these qualifications do you have? 
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€ None 
€ Secondary education or sixth form college  
€ Trade apprenticeship 
€ College or University 
€ Graduate school 
€ Other 
 
 
END OF QUESTIONNAIRE 
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